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In collaboration with divisions in the National Center for Infectious Diseases, the Public
Health Practice Program Office, and the National Institute for Occupational Safety and Health,
the Division of Tuberculosis (TB) Elimination of the National Center for HIV, STD, and TB
Prevention (NCHSTP),* Centers for Disease Control and Prevention (CDC), is the functional
equivalent of a national TB program in the United States. As such, CDC is the federal
government’s lead agency for TB prevention, control, and elimination.
In 1989, CDC published A Strategic Plan for the Elimination of Tuberculosis in the United
States. This plan had been developed by the Advisory Council for the Elimination of
Tuberculosis (ACET) and proposed a national strategy for TB elimination by 2010. The
implementation of this plan was set back by the TB resurgence that occurred in the late 1980s
and early 1990s. This rekindling of TB disease was fueled by the onset of the human
immunodeficiency virus (HIV) epidemic, increases in TB cases among foreign-born persons,
outbreaks in congregate settings, and the appearance and transmission of deadly multidrug-
resistant (MDR) TB strains. These occurred at a time when decades of cuts in TB funding had
resulted in the deterioration of TB control programs, and TB control officials had very few
resources with which to fight back. CDC published the National Action Plan to Combat
Multidrug-Resistant Tuberculosis in 1992 to complement the 1989 TB elimination document.
A renewed downturn in TB incidence since 1993 points to the successful implementation of
these national plans over the past decade. Unprecedented low rates of TB disease now provide a
historic opportunity to accelerate the decline in TB morbidity and the drive toward elimination.
This opportunity is threatened, however, by several converging factors: 1) the retreat of TB into
high-risk populations at the margins of society where it can resist detection, 2) the persistence
and growth of the global TB epidemic, 3) the limitations of current control measures and
recognition of the need for new tests and treatments, plus an improved vaccine, and 4) changes
in the health care system that make the current context for TB elimination very different from
that of a decade ago.
Given this altered landscape, in late 1998 CDC commissioned the Institute of Medicine (IOM)
of the National Academy of Sciences to conduct a study and determine if TB elimination is still
feasible as a national goal and, if so, to provide recommendations on how to make that goal a
reality. The resulting report, Ending Neglect: The Elimination of Tuberculosis in the United
States, concluded that TB elimination in the United States is indeed feasible but will require
“aggressive and decisive action beyond what is now in effect.” To break the “cycle of neglect”
that has characterized U.S. tuberculosis control efforts, the report recommended an aggressive
strategy to 1) maintain control of TB, 2) speed the decline in TB incidence, 3) develop new
tools for TB diagnosis, treatment, and prevention, 4) increase U.S. efforts to help fight the
global epidemic, and 5) mobilize and sustain public support for TB elimination and track
progress.
*NCHSTP provides leadership in preventing and controlling human immunodeficiency virus (HIV) infection, other
sexually transmitted diseases (STDs), and TB.
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Rationale for TB Elimination
TB maintains its grim historical notoriety as one of the leading infectious causes of death
worldwide. Ironically, it is preventable and, in most cases, treatable. Infection-control
precautions can help reduce the risk of TB transmission. Medical treatment of persons with
latent TB infection can prevent the subsequent development of active TB disease. TB disease
can usually be cured with anti-TB drugs taken exactly as prescribed. Even persons with drug-
resistant strains can often be cured by alternative regimens of medications. The downturn in TB
incidence that occurred between 1993 and 2001 is directly attributable to the resources used to
strengthen TB control programs and implement these measures nationwide. The question now
is whether this success will lead to waning interest and another cycle of neglect or provide the
impetus for a final push toward TB elimination.
The continuing social, public health, and economic costs of TB provide a compelling rationale
for TB elimination. Almost 16,000 new cases of TB disease occurred in 2001 in the United
States, and an estimated 10 million to 15 million persons have latent TB infection with the
attendant risk of future disease. Costly TB outbreaks continue to occur in the United States, and
MDR TB continues to spread. TB-related costs approach $1 billion each year in this country.
Nonetheless, TB incidence is presently at an all-time low, and several factors strengthen the
feasibility of and justification for elimination. TB is retreating into geographically and
ethnographically distinct populations that, although hard to reach, can nonetheless be targeted
for prevention and control interventions. Arguments based on social justice support increased
efforts to combat a grave health problem that disproportionately affects disenfranchised
persons. Finally, a U.S. initiative can stimulate other nations to seek the social and economic
benefits to be derived from TB elimination.
CDC’s Response to Ending Neglect: the Elimination of TB in the United
States
This document is CDC’s response to the IOM’s TB elimination challenge. The plan reflects the
scientific, programmatic, and health-sector developments of the last decade and supercedes the
1989 Strategic Plan for the Elimination of Tuberculosis in the United States. The goals,
objectives, and action steps that comprise CDC’s contribution to TB elimination will serve as a
guide for CDC’s work, in collaboration with its partners, to finally rid the nation of the human
suffering and societal harm caused by TB disease.
The plan is organized around six goals that frame TB elimination efforts in the context of the
IOM’s recommendations. The goals and corresponding objectives are as follows:
Goal I: Maintain control of TB
Maintain the decline in TB incidence through timely diagnosis of active TB disease, appropriate
treatment and management of persons with active disease, investigation and appropriate




A. Maintain and enhance local, state, and national public health surveillance for TB.
B. Support the infrastructure needed for laboratory-based identification and treatment of TB.
C. Ensure that patient-centered case management and monitoring of treatment outcomes are
the standard of care for all TB patients.
D. Develop community partnerships, and strengthen community involvement in TB control.
E. Improve the timely investigation and appropriate evaluation and treatment of contacts with
active TB disease and latent TB infection.
F. Ensure appropriate care for patients with MDR TB, and monitor their response to
treatment and their treatment outcomes.
G. Ensure that health care facilities maintain infection-control precautions.
H. Develop improved engineering and personal protective techniques to prevent TB
transmission.
I. Improve TB control in foreign-born populations entering or residing in the United States.
J. Educate the public and train health care providers to maintain excellence in TB services.
Goal II: Accelerate the decline
Advance toward TB elimination through targeted testing and treatment of persons with latent
TB infection, appropriate regionalization of TB control activities, rapid recognition of TB
transmission using DNA fingerprinting methods, and rapid outbreak response.
Objectives:
A. Increase the capacity of TB control programs to implement targeted testing and treatment
programs for high-risk persons.
B. Explore the appropriateness of regionalizing TB control activities in high, intermediate,
and low TB-incidence areas of the United States.
C. Characterize circulating M. tuberculosis strains using DNA fingerprinting methods.
D. Develop national, state, and local capacity to respond to outbreaks of TB.
Goal III: Develop new tools
Develop and assess new tools for the diagnosis, treatment, and prevention of TB.
Objectives:
A. Develop a coordinated plan for TB research.
B. Develop new methods for diagnosing persons with latent TB infection and for identifying
infected persons who are at high risk for developing active TB.
C. Develop and assess new drugs for improving TB treatment and prevention.
D. Develop a new and effective TB vaccine.
E. Develop and implement a program of research on behavioral factors related to TB
treatment and prevention.
F. Rapidly transfer findings from research studies into practice.
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Goal IV: Reduce the global burden of TB
Increase U.S. involvement in international TB control activities.
Objectives:
A. Provide leadership in public health advocacy for TB prevention and control.
B. Provide technical support and build capacity for implementation of the World Health
Organization strategy for TB control (i.e., DOTS), especially in those countries that
contribute significantly to the U.S. TB burden.
C. Develop models for the diagnosis and treatment of patients with MDR TB.
D. Provide technical, programmatic, and research support to reduce the incidence of TB as
an opportunistic disease in high HIV-burden countries.
Goal V: Mobilize and sustain support
Mobilize and sustain support for TB elimination by engaging policy and opinion leaders, health
care providers, affected communities, and the public. Implement a comprehensive health
communication campaign that supports TB elimination and ensures the development and
delivery of effective TB elimination messages. Improve communication efforts through
consistent monitoring and evaluation of the plan’s methods and strategies.
Objectives:
A. Develop and implement a health communications effort focusing on the achievable goal
of eliminating TB, if both political commitment and resources are made available.
B. Help communities foster nontraditional, multisectoral, public-private partnerships to
improve the effectiveness of their communications activities, with particular attention to
culturally appropriate materials.
C. Support the development of state- or area-specific TB elimination plans that contain
communications activities designed to build support for TB elimination.
Goal VI: Track progress
Monitor progress toward the goal of TB elimination, and regularly report on progress to all
target audiences.
Objectives:
A. Develop innovative analyses for examining surveillance data to help focus elimination
efforts.
B. Develop novel indicators of progress toward elimination.
C. Conduct periodic evaluations of TB program performance at federal, state, and local
levels.
D. Conduct an annual progress review.
CDC’s Response to Ending Neglect: The Elimination of Tuberculosis in the United States
complements a separate, more comprehensive, coordinated federal response to the IOM’s
recommendations by providing more detail on CDC’s part of the federal strategy.





Tuberculosis (TB), once the leading cause of death in the United States, appeared to be
receding into history by the latter part of the 20th century. Thanks to improved social and
economic conditions and the development of effective drugs, TB case counts had fallen off so
dramatically by the 1980s that U.S. TB experts believed TB could be virtually eliminated from
the United States by the year 2010. The Advisory Council for the Elimination of Tuberculosis
(ACET) developed and outlined these projections in A Strategic Plan for the Elimination of
Tuberculosis in the United States, which was published by the Centers for Disease Control and
Prevention (CDC) in 1989. In this document, ACET proposed a national strategy for TB
elimination, defined as an incidence rate of less than one TB case per 1 million persons per
year.1 Actions to achieve that goal centered on making better use of existing TB prevention and
control methods; creating and evaluating new tools for diagnosing, treating, and preventing TB;
and rapidly applying these tools to clinical and public health practice.
The implementation of this plan was set back by the unexpected resurgence of TB that occurred
in the mid 1980s and early 1990s. The reversal of the longstanding downward trend in TB
incidence was fueled by several converging factors: the onset of the human immunodeficiency
virus (HIV) epidemic, increases in TB cases among foreign-born persons, outbreaks in
congregate settings (e.g., hospitals, correctional facilities, hospices), and delays in recognizing
the appearance and transmission of deadly, drug-resistant TB strains that defy traditional
treatments.2-4 At the same time, premature cuts in TB funding and the subsequent deterioration
of TB prevention and control programs impaired the ability of these programs to respond to the
resurgent TB. The National Action Plan to Combat Multidrug-Resistant Tuberculosis was
promptly developed and published in 1992 to complement the 1989 TB elimination plan.5
During the past decade, these plans have guided the nation’s TB control programs and propelled
its mobilization against the resurgent TB. Efforts to implement the strategies recommended in
these plans have been largely successful, as evidenced by a renewed downturn in TB
incidence).6,7 Nonetheless, some emerging changes in the features and management of TB in
the United States are challenging control efforts and threatening to thwart the drive toward
elimination:
 As numbers of TB cases have steadily dropped, the disease has retreated into localized
areas and population groups who may be hard to reach using the traditional public health
approaches, so that it can lie hidden and resist detection. The persistence of TB in these
high-risk populations poses threats for yet another widespread comeback.
 Although screening and treatment efforts have led to great progress in blocking the spread
of TB, it has become increasingly clear that elimination will require better tests and
treatments, plus an improved vaccine.8
 Despite falling numbers of cases in the United States and in a few other resource-rich
countries, the global TB epidemic continues to rage in many other countries, and remains
an important source of new U.S. cases in the person of immigrants and refugees. As of
2001, TB cases in foreign-born persons now account for at least 50% of all cases
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reported in the United States annually.7 In contrast to the marked decline in TB case rates
in U.S.-born persons, the TB control measures implemented in the early 1990s have had
little impact on TB case rates in foreign-born persons.9
 Changes in the organization, delivery, and financing of health care brought about by the
shift to managed care make the current context for TB prevention, control, and
elimination very different from that of a decade ago.10
Given this altered landscape, in late 1998 CDC commissioned the Institute of Medicine (IOM)
of the National Academy of Sciences to conduct a study to determine if TB elimination is still
feasible as a national goal and, if so, to provide recommendations for making that goal a reality.
In the resulting report, Ending Neglect: The Elimination of Tuberculosis in the United
States,11 the IOM concluded that TB elimination in the United States is indeed feasible but that
meeting this goal will require “aggressive and decisive action beyond what is now in effect.”
Current efforts in TB control will not be sufficient, and doing less could be disastrous. To
break the “cycle of neglect” that has characterized U.S. tuberculosis control efforts, the report
recommended an aggressive campaign to release TB’s tenacious grip on the nation.
At the current rate of decline in TB incidence, it is estimated that it will take at least 70 years
to reach the U.S. elimination goal of less than 1 case per million population by the target year
of 2010. To speed progress toward elimination, the IOM pressed for an acceleration in the rate
of reduction in the incidence of new TB cases. Stepping up the pace would yield numerous
benefits to the nation11 by reducing the
 Number of persons suffering with TB
 Costs of medical care for TB patients
 Risk of a resurgence of TB
 Risk of multidrug-resistant TB (MDR TB)
 Risk of spread to TB-free areas of the United States
 Complications caused by TB in HIV-infected persons
Additionally, it would contribute to a reduction in the global burden of TB and hasten the
eventual elimination of TB from the United States.
CDC’s Response to Ending Neglect: The Elimination of Tuberculosis in the United States
outlines the background and rationale for eliminating TB in the United States and presents the
goals, objectives, and action steps that comprise CDC’s new strategy for TB elimination. The
plan will serve as a guide for CDC’s work, in collaboration with its partners, to finally rid the
nation of the human suffering and societal harm caused by TB disease.
TB: A Preventable and Treatable Disease
Tuberculosis is a contagious and potentially life-threatening infectious disease caused by
bacteria of the Mycobacterium tuberculosis complex. The bacteria that cause TB are spread
from person to person through the air. People with TB disease of the lungs or larynx spray the
bacteria into the area when they cough, sneeze, talk, or otherwise expel air, dispersing droplets
containing M. tuberculosis. People nearby can breathe the infectious droplets into their lungs
and become infected. Infection usually requires prolonged contact in a confined area with a
person who is actively expelling TB bacteria into the air. In rare cases, TB infection has been
documented after short exposures to persons with active TB.12,13
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In most infected persons, merely harboring TB organisms is not enough to cause symptoms or
to produce an active case of the disease. The body’s immune system is usually able to contain
the infection but may not be able to eliminate it without help from anti-TB drugs. A person with
latent TB infection remains infected until correct treatment is completed. Without treatment,
infected persons can develop active, clinical disease at any time. The persons most likely to
become ill are those whose immune systems have been weakened by illness, old age, or
malnutrition. To spread TB to others, a person must have active TB disease.
TB maintains its grim historical notoriety as one of the leading infectious causes of death
worldwide; yet, it is preventable and, in most cases, treatable. Infection-control precautions can
help reduce the risk of TB transmission. Treatment of persons with latent TB infection can
prevent the subsequent development of active TB, and TB disease can usually be cured with
available anti-TB drugs. Even persons with drug-resistant strains can often be cured by
alternative regimens of medications. Nonetheless, TB continues to menace Americans. Several
closely interconnected social, political, and medical factors persist in fueling disease
transmission and imperiling elimination goals.
Cycles of Resurgence and Control
The resurgence of the U.S. TB epidemic that occurred in the late 1980s had its origins in the
complacency of the early 1970s. When medical advances and improved societal conditions
seemed to be controlling TB by the 1960s, funding dedicated to fighting the disease was
prematurely cut. The result was a breakdown in control efforts in many parts of the country. TB
soon returned with a vengeance. Disease rates jumped, deadly drug-resistant strains emerged,
and new outbreaks in the late 1980s quickly turned into an epidemic that cost billions of dollars
to control3, 14 and also cost many people their health or even their lives. Hundreds of difficult-
and expensive-to-treat drug-resistant cases developed. The nation had dropped its guard, and a
preventable and treatable disease had once again turned deadly.
Studies conducted during the period of resurgence (1985-1992) indicated substantial ongoing
transmission of TB and development of disease in larger-than-expected numbers in recently
infected persons.15, 16 However, in a pattern suggesting the existence of several concurrent U.S.
epidemics, the phenomenon appeared to be mainly affecting certain high-risk populations:
HIV-infected persons (TB thrives in a weakened immune system), foreign-born persons
(people from areas where TB is common often
have latent TB infection), homeless persons
(TB is easily spread in the crowded confines
of homeless shelters), and persons living in
congregate settings (persons with
unrecognized or undiagnosed TB are often
housed among susceptible people in close
quarters). The increase in the number of
persons with drug-resistant TB was attributed
largely to institutional outbreaks involving
persons with HIV infection.3, 4 The rise in total
cases, coupled with increased drug resistance,
created formidable challenges for state and
local control programs.5
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The comeback of TB prompted the mobilization of improved prevention and control efforts.
These centered on rapid identification of persons with TB, initiation of appropriate treatment,
and implementation of strategies such as directly observed therapy (DOT) to ensure that
patients complete their treatment.17, 18, 19 Many areas expanded their TB screening and treatment
efforts directed toward high-risk groups, especially persons at risk for HIV infection and those
in correctional facilities. Surveillance data and research on adherence to treatment further
characterized risk groups, leading to more targeted interventions. In parallel with these
surveillance and research activities, public health agencies produced much-needed training and
educational products for health care providers, with timely development of materials to reflect
clinical advances and changing TB epidemiology. ACET and CDC jointly issued a series of
statements on TB control practices, and three Model TB Centers were established as national
resources for TB services, consultation, and training. As a result, cases have dropped each year
since 1993, reaching an all-time low in 2001.7
Challenges to Elimination
The downturn in TB incidence that has occurred since 1993 is directly associated with the
increased resources used to strengthen state and local TB control programs nationwide.11 The
question now is whether this success will lead to complacency, then to waning interest and
another cycle of neglect, or provide the impetus for a final push toward TB elimination. At a
minimum, future planning for TB control will have to address several recalcitrant problems.
Proven and essential measures that would improve the timely completion of TB treatment are
underused in many areas.20 In addition, the investigation of contacts of infectious cases and the
treatment of persons with latent TB infection are often inadequate.21,22 In some areas where TB
case counts have been declining, an erroneous and dangerous perception is again emerging that
TB may no longer be a serious problem requiring sustained resources. With such perceptions,
we risk losing what we have recently gained.
The marked changes in the provision and financing of health care in the United States that have
come about as a result of managed-care policies and practices during the past decade present
added challenges for TB control. Nearly 80 million Americans are now enrolled in health-
maintenance organization plans.10 Managed-care programs serve one third of Medicaid
beneficiaries, with enrollment in such programs growing at the rate of 30% to 40% annually.23
The opportunity exists for TB control programs to work with managed-care programs in the
provision of high-quality — and potentially cost-saving — preventive TB services to high-risk
persons.24, 25 However, it is uncertain to what extent these organizations will support optimal TB
surveillance and reporting, as well as provide treatment and prevention services. Additionally,
the large numbers of uninsured persons not covered by managed-care plans pose an ongoing
challenge to TB prevention and control efforts.
TB control is also hampered by inefficient and outdated diagnostic tools. The current TB skin
test takes 2 days to complete, is difficult to read, and is often inaccurate in populations with a
low prevalence of TB. Technological advances can help speed the way toward TB elimination,
but methods for optimizing the use of new technology are still being evaluated. The past decade
has seen notable advances in TB diagnostics, including the development of new methods that
greatly reduce the time needed to detect the growth of TB organisms in diagnostic
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specimens.26-27 Rapid methods for identifying drug-resistant TB are under investigation,28, 29 and
new blood tests for detecting latent TB infection show promise.26, 27, 29-33 DNA fingerprinting
methods have been used to identify M. tuberculosis strains implicated in outbreaks, and the
role of these methods in detecting ongoing community TB transmission is being assessed.32, 34
The TB drug development process is moving more slowly than diagnostics development.
Scientists have made advances in describing the mechanisms of drug actions and drug
resistance, and these advances are contributing to the development of new types of anti-TB
drugs. In 1997, CDC established the TB Trials Consortium (TBTC) and tasked it with
undertaking clinical trials of new drugs for TB treatment and prevention in the United States.
TBTC data assisted the Food and Drug Administration (FDA) in its evaluation in 1998 of
rifapentine, the first new TB drug approved in more than 25 years.35 Clinical trials of “short-
course” treatment for latent TB infection have led to CDC recommendations for the use in
selected settings of a 2-month regimen of the anti-TB drugs rifampin and pyrazinamide as an
alternative to longer courses of isoniazid.36 Unfortunately, despite the need for new drugs, too
few pharmaceutical companies are involved in TB drug development.37
A significant research effort is being directed to the development of new TB vaccines. The
successful decoding of the complete genome of M. tuberculosis should accelerate the process
of vaccine development,38 and several candidate vaccines will likely be available soon for
human testing. In 1998, the National Institutes of Health (NIH), together with the National
Vaccine Program Office (NVPO) and ACET, issued the Blueprint for Tuberculosis Vaccine
Development.39 The agencies concluded that a safe and protective TB vaccine could be
developed but that the effort would require a sustained and substantive commitment (20 years
and approximately $800 million) and international and public-private sector collaboration.
Most importantly, the United States’ recent success in TB control is tempered by the heavy
impact of TB in foreign-born persons living in the country. The global burden of TB is
staggering, with nearly 8 million new cases and 2 million deaths each year.40 As the number of
cases in indigenous persons drops, an increasing percentage of U.S. cases is occurring in
persons from Asian, Latin American, and African countries, where TB rates are
5 to 30 times those of the United States.41 The TB case rate for foreign-born persons in the
United States has remained at least four to five times higher than that for U.S.-born persons,
and the proportion of U.S. TB cases occurring in foreign-born persons has increased steadily
since the mid-1980s.9 In 2001 the
proportion of TB cases among
foreign-born persons living in the
United States had reached 50%
(see graph).7
TB elimination in the United States
will therefore not be possible
without a substantial reduction in
the global burden of TB. Global TB
control efforts are, however,
hampered by a combination of
barriers. Foremost among these is
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some TB-affected nations to develop the political will needed, and of some donor nations to
provide the financial resources needed, for effective TB control. The World Health
Organization (WHO) estimates that in 1997 only 32% of the world’s population lived in areas
where effective TB control programs were fully operational.42 In much of sub-Saharan Africa,
HIV has led to the doubling and tripling of TB cases, threatening to collapse unstable TB
control programs.43 To date, it appears that none of the strategies for TB control recommended
for low-income countries have stemmed the tide of HIV-associated TB. Increases in drug-
resistant TB add urgency to the push for effective interventions worldwide.40, 44
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How to Eliminate TB? – The IOM Report
The IOM report Ending Neglect: The Elimination of Tuberculosis in the United States11
reviewed the lessons learned from the neglect of TB between the late 1960s and early 1990s
and reaffirmed the necessity of a commitment to the goal of TB elimination. The IOM
emphasized, however, that TB elimination will require a new level of resources and intersector
collaboration. The authors called on the federal government to “set the pace in fostering efforts
to manage and prevent tuberculosis” and identified five areas for decisive action.
Maintain Control of TB
“...without question the major reason for the resurgence of tuberculosis was the deterioration of the public
health infrastructure essential for the control of tuberculosis.” p. 2
In the 1970s and early 1980s, the country became complacent about TB, and many states and
cities redirected TB prevention and control funds to other programs. Consequently, the trend
toward elimination was reversed, and the nation experienced a TB resurgence. To maintain
control of TB, the IOM recommended
 Mandating completion of therapy for all patients with active TB
 Evaluating case-management systems used in TB control efforts in new ways
 Regionalizing TB control activities
 Retaining federal categorical funding for TB control
 Educating the public, and training health care providers to maintain excellence in TB
services
Accelerate the Decline
“At the current rate of decline, approximately 6 percent per year, it will take more than 70 years to reach the
target for elimination of tuberculosis of 1 case of tuberculosis per million population.” p. 122
Maintaining control of TB is not enough to eliminate it. People can unknowingly carry TB
organisms for years. Finding and treating the estimated 10 million to 15 million Americans
with latent TB infection before they become sick — and infectious — is essential to
eliminating TB. To speed the decline of TB, the IOM recommended
 Developing better ways to find persons who have been in close contact with someone with
infectious TB and, if needed, treat them for latent infection
 Performing TB skin testing as part of the medical examination for immigrants from
countries with high rates of TB
 Performing TB skin testing in inmates of correctional facilities




“...the greatest needs in the United States are new diagnostic tools for the more accurate identification of
individuals who are truly infected and who are also at risk of developing tuberculosis.” p. 122
The goal of TB elimination cannot be reached with currently available tools. State-of-the-art
tools are needed, such as
 Effective tests for latent TB infection and improved methods to determine who will
progress from latent TB infection to TB disease
 New drugs to shorten and simplify treatment of both latent TB infection and active TB
 An effective vaccine to prevent infection and active disease
 Behavior-change models to influence at-risk persons and their health care providers
Increase Involvement in Global Efforts
“Although an altruistic argument for promoting the global control of tuberculosis can easily be advanced,
worldwide control of this disease is also in the nation’s self-interest.” p. 149
The United States will never be able to eliminate TB until the global epidemic is under control.
The IOM therefore recommended
 Supporting training in TB control in countries with high rates of disease
 Supporting WHO’s TB-control initiative
 Targeting resources by development and use of a multiagency strategic plan
Mobilize and Sustain Support
“Only an aggressive effort aimed at building political commitment can prevent the elimination of funding for
tuberculosis research...before the elimination of the disease, leading to yet another period of neglect.” p. 4
Underlying all of these actions must be a concerted effort to educate the public that TB
elimination is achievable, promote scientific consensus on what needs to be done, establish
partnerships with leaders of affected groups, and use the media to create public interest. The
IOM recommended
 Increasing resources for activities designed to secure and sustain public understanding of
and support for TB elimination
 Securing the participation of nontraditional partners
 Tracking progress toward elimination
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Why Eliminate TB? – Rationale for TB Elimination
The continuing social, public health, and economic costs of TB provide a compelling rationale
for TB elimination. Thousands of new cases of TB disease still occur every year in the United
States — there were almost 16,000 in the year 2001 — and an estimated 10 million to 15
million persons have latent TB infection with the attendant risk of future disease. Costly TB
outbreaks continue to occur in the United States, and MDR TB continues to spread. Despite
recent progress, 43 states and the District of Columbia reported at least one MDR TB case
between 1993 and 1997.45 As a consequence, the cost of TB in the United States is estimated to
approach $1 billion yearly.2
At present, TB incidence is at an all-time low, and several factors favor the feasibility of the
elimination goal. TB is retreating into geographically and ethnographically distinct populations
that can be targeted for effective prevention and control interventions. Such targeted
interventions are likely to yield excellent results and be cost-effective in further reducing the
incidence of TB. A commitment to eliminate TB also reflects society’s willingness and ability
to combat a grave health problem that disproportionately affects disenfranchised persons. A
desire for social justice and the recognition of widespread racial and ethnic disparities in the
incidence of TB in the United States argue for more effective TB control and for political
action that addresses the root causes of the disparities.46
Finally, elimination of TB from the United States evokes the greater vision of worldwide
eradication of TB. A U.S. elimination initiative could serve as encouragement to other nations
that are aware of the social and economic benefits of a healthy, long-lived population and the
social justice that would be served by eliminating TB.
Who Will Lead? – CDC’s Response
In collaboration with divisions in the National Center for Infectious Diseases, the Public
Health Practice Program Office, and the National Institute for Occupational Safety and Health,
the Division of TB Elimination of the National Center for HIV, STD, and TB Prevention, CDC,
is the functional equivalent of a national TB program in the United States.47 As such, CDC is the
federal government’s lead agency for TB prevention, control, and elimination. Several other
federal agencies share crucial roles in contributing to TB prevention and control and its
eventual elimination. For example, the FDA approves new drugs and diagnostics and ensures
drug quality, the Health Resources and Services Administration (HRSA) and Health Care
Financing Administration (HCFA) facilitate access to and financing of health care, and the NIH
conducts and supports biomedical research and health care worker training. These and several
other agencies form part of the Federal TB Task Force, the members of which coordinate
federal TB activities in the United States.
Although current activities to control TB are yielding significant results nationwide, CDC
recognizes that TB elimination will require sustained effort, long-term commitment, new tools,
and strong partnerships with other federal health agencies and state and local health
departments. This document, CDC’s Response to Ending Neglect, describes CDC’s new
strategy for achieving TB elimination, taking into account the challenges, advances, and
collaborations of the past and building on them.
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The plan reflects the scientific, programmatic, and health-sector developments of the last
decade and supersedes the 1989 Strategic Plan for the Elimination of Tuberculosis in the
United States. The response details the CDC priority activities required for the elimination of
TB in the United States in the context of the recommendations issued by the IOM report
Ending Neglect and is organized around six goals and corresponding objectives (Table 1):
I. Maintain control of TB
II. Accelerate the decline
III. Develop new tools
IV. Increase involvement in global efforts
V. Mobilize and sustain support
VI. Track progress toward elimination
CDC’s Response to Ending Neglect complements a more comprehensive federal plan to
respond to the IOM’s recommendations. Implementation of these plans should set in motion
the activities needed to arrest TB in the United States.
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Table 1. CDC’s Response to Ending Neglect: The Elimination of Tuberculosis in the
United States. Summary of Goals and Objectives
Goal I: Maintain control of TB
Objectives:
A. Maintain and enhance local, state, and national public
health surveillance for TB.
B. Support the infrastructure needed for laboratory-based
identification and treatment of TB.
C. Ensure that patient-centered case management and
monitoring of treatment outcomes are the standard of
care for all TB patients.
D. Develop community partnerships, and strengthen
community involvement in TB control.
E. Improve the timely investigation and appropriate
evaluation and treatment of contacts with active TB
disease and latent TB infection.
F. Ensure appropriate care for patients with MDR TB,
and monitor their response to treatment and their
treatment outcomes.
G. Ensure that health care facilities maintain infection-
control precautions.
H. Develop improved engineering and personal
protective techniques to prevent TB transmission.
I. Improve TB control in foreign-born populations
entering or residing in the United States.
J. Educate the public and train health care providers to
maintain excellence in TB services.
Goal II: Accelerate the decline
Objectives:
A. Increase the capacity of TB control programs to
implement targeted testing and treatment programs for
high-risk persons.
B. Promote the appropriate regionalization of TB control
activities in high, intermediate, and low TB-incidence
areas of the United States.
C. Characterize circulating M. tuberculosis strains using
DNA fingerprinting methods.
D. Develop national, state, and local capacity to respond
to outbreaks of TB.
Goal III: Develop new tools
Objectives:
A. Develop a coordinated plan for TB research.
B. Develop new methods to diagnose persons with latent
TB infection and to identify infected persons who are
at high risk for developing active TB.
C. Develop and assess new drugs to improve TB
treatment and prevention.
D. Develop a new and effective TB vaccine.
E. Develop and implement a program of research on
behavioral factors related to TB treatment and
prevention.
F. Rapidly transfer findings from research studies into
practice.
Goal IV: Increase involvement in global efforts
Objectives:
A. Provide leadership in public health advocacy for TB
prevention and control.
B. Provide technical support and build capacity for
implementation of DOTS, especially in those countries
that contribute significantly to the U.S. TB burden.
C. Develop models for the diagnosis and treatment of
patients with MDR TB.
D. Provide technical, programmatic, and research support
aimed at reducing the incidence of TB as an
opportunistic disease in high HIV-burden countries.
Goal V: Mobilize and sustain support
Objectives:
A. Develop and implement a health communications
campaign focusing on the resources and support
needed to eliminate TB.
B. Help communities foster nontraditional, multisectoral,
public-private partnerships to improve the
effectiveness of their communications activities, with
particular attention to culturally appropriate materials.
C. Support the development of state- or area-specific TB
elimination plans that contain communications
activities to build support for TB elimination.
Goal VI: Track progress toward elimination
Objectives:
A. Develop innovative analyses for examining
surveillance data to help focus elimination efforts.
B. Develop novel indicators of progress toward
elimination.
C. Conduct periodic evaluations of TB program
performance at federal, state, and local levels.
D. Conduct an annual progress review.
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The Plan
GOAL I: Maintain control of TB
Maintain the decline in TB incidence through timely diagnosis of active TB disease, appropriate
treatment and management of persons with active disease, investigation and appropriate
evaluation and treatment of contacts of infectious cases, and prevention of transmission
through infection control.
Tuberculosis control efforts have two priorities: 1) to detect persons with active TB and treat
them with effective anti-TB drugs, and 2) to identify contacts of infectious TB cases and
evaluate and treat them as needed.
Effective treatment cures patients of TB disease and stops the transmission of infection to
others. Being treated for active TB involves taking multiple anti-TB drugs daily or several times
a week for at least 6 months. Anti-TB drugs must be prescribed properly and taken for the full
treatment period. Otherwise, the disease may not be cured and could recur. Also, the TB
organisms could become resistant to standard anti-TB drugs. To maintain control of TB and
prevent drug-resistant disease, TB must be accurately diagnosed, an effective treatment
regimen must be prescribed, and patients must take all of their medicine. The best way to
ensure that patients adhere to anti-TB drug regimens is to provide a patient-centered approach
that uses DOT, meaning that a provider watches the patient take the medication.
Contact investigation and follow-up are important for detecting cases of active TB and
identifying persons who have latent TB infection and are at high risk for developing TB disease.
The identification of every infectious or suspected case of TB should prompt an epidemiologic
investigation to locate others who have potentially been exposed and are therefore at risk of
infection. To maintain control of TB, contacts of potentially infectious TB cases must be
evaluated and, if found to be infected, treated appropriately.
Objective I-A
Maintain and enhance local, state, and national public health surveillance for TB.
State and local health departments are legally responsible for protecting the public health.48 In
the setting of active TB, this responsibility includes 1) ensuring that each patient with active TB
completes appropriate treatment, 2) ensuring that a contact investigation is conducted to
identify other persons with potentially infectious TB, 3) arranging for the evaluation and
treatment of persons with active TB or latent TB infection, and 4) conducting epidemiologic
investigations in response to potential outbreaks and implementing control and prevention
measures.
The foundation for these activities is public health surveillance (the ongoing, systematic
collection, analysis, interpretation, and dissemination of health data). TB surveillance is critical
for ensuring complete case finding, appropriate linkages to diagnostic and treatment services
and contact investigations, and reliable information systems for monitoring TB trends and
evaluating control programs. All states require designated health care professionals to report
TB cases (and usually suspect TB cases) to local or state health departments.48 All state health
departments maintain TB surveillance systems. The extent of local surveillance activities
depends on state statutes and the delegation of authority by state health departments. States and
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localities provide information on the numbers and characteristics of TB cases to the national
surveillance system at CDC. The national system plays a critical role in monitoring national TB
trends and guiding the planning and evaluation of national TB control efforts.
Ensuring that the surveillance system captures all persons with TB requires active case finding
(also called active surveillance). Active case finding is a particularly important activity when
the number of cases is decreasing and disease elimination is the goal. Active case finding can
be supplemented by screening of high-risk populations.
Activities
1. Assist state and local health departments in periodic evaluations of TB surveillance
systems.
2. Maintain support for the national TB surveillance system.
3. Conduct comprehensive and standardized evaluations of surveillance activities in all
50 states, the District of Columbia, and U.S. territories to help in the development and
implementation of strategies to improve and enhance surveillance, especially active
surveillance.
Objective I-B
Support the infrastructure needed for laboratory-based identification and treatment
of TB.
TB control efforts depend on well-functioning mycobacteriology laboratories that can
1) detect, isolate, and identify TB organisms, 2) determine the organisms’ susceptibility to
anti-TB drugs, and 3) communicate promptly with clinicians so that diagnoses can be
confirmed and treatment started. Both the laboratory and the clinician should have confidence
in a laboratory’s results. Accordingly, laboratories must institute efficient procedures, refer
specimens to referral laboratories when necessary, and be adequately staffed to provide results
in a rapid and efficient manner. All mycobacteriology laboratories must participate in
recognized proficiency testing programs and establish levels of service that reflect the
demonstrated quality of performance.
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Diagnostic Standards and Classification of Tuberculosis
in Adults and Children
In April 2000, CDC and the American Thoracic Society (ATS) published Diagnostic
Standards and Classification of Tuberculosis in Adults and Children.49 These standards
are designed to provide a framework for and an understanding of the diagnostic approaches to
latent TB infection and disease and to present a classification scheme that facilitates patient
management. A person classified as having “clinical active TB” (Class 3) must have clinical,
bacteriologic, or radiographic evidence of current TB. The bacteriologic evidence is
established by isolation of M. tuberculosis in a fully functioning mycobacteriology laboratory.
Activities
1. Sustain state and local health department laboratories, and upgrade them as necessary.
 Continue to support state and local health departments’ mycobacteriology
laboratories through cooperative agreements.
 Strengthen the ability to provide technical support to state and local
mycobacteriology laboratories.
 Ensure the availability of back-up services to state and local mycobacteriology
laboratories as needed.
 Support the development of effective quality assurance and training programs for all
laboratories that process mycobacteria specimens.
2. Enhance laboratory capacity to support outbreak investigations.
 Continue to support TB outbreak investigations through DNA fingerprinting and
enhanced drug-susceptibility testing.
 Develop strategies for transferring technologies for DNA fingerprinting to state and
city health departments, as appropriate.
 Support regional laboratories that provide DNA fingerprinting services to state and
local TB control programs.
3. Evaluate and support new approaches to providing reliable and timely laboratory services
for TB diagnosis.
 Monitor laboratory practices and capabilities in state and territorial mycobacteriology
laboratories to determine work volume and proficiency levels.
 Conduct operational studies in order to develop models for referring specimens and
cultures that ensure rapid test results for smears, culture identification, and drug
susceptibility testing, as well as studies to explore the feasibility of alternate
approaches to providing laboratory services for TB diagnosis at the local, state, and
regional levels.
 Establish mechanisms for the timely feedback of laboratory results to health
departments and clinicians charged with the care of TB patients and suspected TB
patients.
 Ensure that CDC has appropriate laboratory staff for conducting operational research




Ensure that patient-centered case management and monitoring of treatment outcomes
are the standard of care for all TB patients.
Promoting patient-centered case management involves assessing each TB patient’s needs and
identifying a treatment plan that ensures the completion of therapy. High rates of completion of
TB treatment (exceeding 90%) are most likely when treatment incorporates DOT, with multiple
enablers (something that helps the patient complete treatment, e.g., transportation vouchers),
incentives (something that will motivate the patient to successfully carry out program goals,
e.g., food coupons), and other treatment enhancers (e.g., alternative treatment delivery sites,
strategies to overcome social and cultural barriers to completion of treatment, use of outreach
workers).18 DOT has been shown to be more effective than self-administered therapy in several
observational studies in the United States18,50 and also to be a cost-effective and, in some cases
potentially cost-saving, alternative to self-administered therapy.51
Activities
1. Ensure that all patients with active TB are tested for HIV infection and that all patients
with TB disease and HIV infection are appropriately and adequately treated.
2. Promote the use of enhanced DOT, including incentives and enablers, to ensure the
completion of treatment in persons with active TB.
 Continue to support DOT, including the use of incentives and enablers, through CDC
cooperative agreement grants.
 Where possible, provide housing for homeless TB patients, e.g., through Housing
Opportunity for Persons with AIDS programs (administered by HUD).
 Support the infrastructure needed to provide well-trained outreach workers.
 Encourage DOT in primary-care facilities, drug treatment centers, HIV/AIDS
residential facilities, HIV clinics, migrant clinics, and shelters.
 Provide ongoing technical assistance, both on-site and by telephone, to promote the
expanded use of DOT by health departments and other providers in the field and in
clinics and other sites.
Effectiveness of Enhanced DOT
The Public Health Tuberculosis Guidelines Panel reviewed 27 studies in which treatment
completion for TB was used as an outcome.18 The studies classified treatment strategies into
four categories: enhanced DOT, DOT, modified DOT, and unsupervised therapy. Enhanced
DOT was defined as a comprehensive, patient-centered strategy of fully supervised DOT
with multiple incentives and enablers. DOT was defined as fully supervised DOT without
incentives or enablers. Modified DOT included DOT for only part of the treatment period, and
unsupervised therapy involved no DOT. The median treatment completion rate for enhanced
DOT was 90%, compared to rates of 86%, 81%, and 61% for DOT, modified DOT, and
unsupervised therapy, respectively.
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3. Develop guidelines and standards for patient-centered case management in public health
clinics, managed-care settings, and other private sector settings.
 Compile and review published studies of patient-centered case management.
 Review effective models of patient-centered case management in state and local TB
programs.
 Convene a national meeting of TB controllers, TB nurse consultants, and clinicians
experienced in TB care to develop guidelines and standards for patient-centered case
management.
 Through ACET, issue guidelines and standards for patient-centered case management.
4. Develop the capacity of state and local TB control programs to conduct systematic and
comprehensive reviews of the outcome of treating patients with active TB (i.e., “cohort
reviews”).
 Provide ongoing technical assistance to promote the use of cohort reviews of patients
with active TB disease to monitor treatment outcomes.
 Develop guidelines, models, and training materials for developing programmatic
capacity to conduct cohort reviews.
5. Develop case-management information systems to facilitate the appropriate management
of patients and the evaluation of their treatment outcomes.
 Define the elements needed for effective case management and evaluation of case-
management systems.
 Develop an information system that captures these elements and promotes the
effective management of patients with active TB.
 Provide financial and technical support to allow programs to establish and use case-
management information systems.
6. Explore ways to increase third-party reimbursement for TB services.
 Conduct a study to 1) identify funding sources for outpatient TB services in a sample
of TB cases, 2) determine facilitating factors and barriers to third-party billing and
reimbursement, and 3) determine the current programmatic and fiscal impact of
reimbursement.
 Using study results, develop recommendations for strategies to maximize and
improve third-party reimbursement for TB control activities.
Objective I-D
Develop community partnerships, and strengthen community involvement in TB
control.
Because each community has its own TB management needs, optimal TB prevention and
control activities require a multifaceted, multidisciplinary approach. Collaborative efforts
between TB prevention and control programs and community groups, health care providers,
and other organizations serving TB patients can 1) educate the public about TB, 2) ensure that
community leaders, health care providers, and policy makers are knowledgeable about TB,
3) identify persons with TB disease and ensure that they complete appropriate treatment,
4) identify contacts of persons with infectious TB disease and ensure that they are
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appropriately evaluated and treated, and 5) coordinate, and in some instances provide, screening
and prevention services for persons at high risk for developing TB disease.
Public health activities that are culturally appropriate and have broad-based community support
have been shown to have a substantial effect on the health status of high-risk communities. Too
often, TB patients and high-risk persons are suspicious or simply unaware of TB prevention and
control services that are available to them. To ensure the quality, effectiveness, and
appropriateness of activities, TB prevention and control programs need help from local groups
in high-prevalence communities. Partnerships with community-based organizations (CBOs) and
with health care providers with established relationships in the community can help ensure that
high-risk populations have access to TB prevention services and that the services reflect local
needs.
Activities
1. Promote the development of partnerships between local TB control programs and
community-based health centers and organizations.
 Develop local epidemiologic profiles of TB disease and infection to assist in the
identification of high-risk groups and of health care providers with whom partnerships
should be established.
 Identify gaps in services to high-risk groups that can be met by the development of
partnerships.
 Emphasize partnership development in cooperative agreement announcements,
program reviews, and site visits.
 Assist in developing the capacity of state and local TB prevention and control
programs to evaluate community partnerships.
 Assist state and local health departments in increasing the capacity of CBOs to deliver
TB services.
 Ensure that local TB control programs develop working partnerships with Ryan-White
providers and other HIV-care providers.
2. Ensure that community-based health care providers are trained in the diagnosis and
treatment of TB disease and latent TB infection.
 Conduct formative research on culturally appropriate training for community-based
health care providers who serve diverse populations.
 Develop training targeted to community-based health care providers.
 Continue to support the National TB Model Centers’ development of culturally
appropriate training materials.
 Support efforts by state and local TB control programs to identify and provide training
to community-based health care providers, including CBOs.
 Support efforts by HIV/AIDS providers funded under the Ryan-White Care Act
Program and other HIV-care providers to ensure adequate and appropriate treatment,




In 1992, the New York State Department of Health created a network of public and private
community providers to deliver DOT services to TB patients. The DOT Provider Network
includes CBOs, social service providers, and advocacy organizations that were already
serving high-risk, hard-to-reach persons. This network has allowed New York to offer DOT
both at fixed treatment centers (e.g., chest clinics, drug treatment centers) and, through
outreach, at locations convenient to the persons being served. Providers are reimbursed
through Medicaid and work closely with the local health department. More than 20 institutions
representing at least 70 fixed treatment centers have become part of the network and now
provide outreach services. More than 1,700 referrals to the network were reported by the end
of 1993. Efforts to maximize referrals and expand the network are ongoing. New alliances
between DOT providers and CBOs can establish support systems for patients, promote
adherence to therapy, and address the health and social problems that place clients at high risk
for TB.
Objective I-E
Improve the timely investigation and appropriate evaluation and treatment of contacts
with active TB disease and latent TB infection.
Contacts of persons with infectious TB are at high risk for infection and disease. The risk to
contacts is related to the infectiousness of the source patient, the characteristics of the
contact, and the characteristics of the environment they share. Prompt identification and
evaluation of contacts of infectious cases are essential for good TB control. This is especially
true for vulnerable high-risk populations. For example, HIV-infected contacts who are also
infected with M. tuberculosis can develop clinically active disease very rapidly, as early as
20 days after infection.52 The priority, speed, and extent of a contact investigation should
reflect the likelihood of transmission (based on the characteristics of the source patient,
contact, and environment) and the possible consequences of infection (especially for HIV-
infected contacts and young children).
Activities
1. Develop guidelines and standards for contact investigations.
 Review guidelines and standards for contact investigations developed by state and
local TB control programs.
 Develop draft recommendations and guidelines for conducting contact investigations.
 Seek comments on the recommendations and guidelines from state and local TB
control officials, health departments, ACET, the National Tuberculosis Controllers
Association (NTCA), and others as appropriate.
 Publish the recommendations/guidelines for contact investigations.
2. Enhance the capacity of state and local TB control programs to conduct contact
investigations, and ensure that infected contacts complete TB treatment.
 Provide funding for enhanced contact investigation and treatment of infected contacts
through CDC’s cooperative agreement grants.
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 Provide ongoing technical assistance to health departments, both on-site and by
telephone, to promote expanded contact investigations.
 Develop and support training for TB control program staff to enhance their ability to
interview and investigate contacts.
 Conduct behavioral research to investigate reasons for nonadherence with curative
treatment and treatment of latent TB infection; develop interventions to increase
adherence.
 Develop the capacity of TB controllers to use social network analysis in contact
investigations
3. Develop the capacity of state and local TB control programs to evaluate the outcomes of
contact investigations and respond appropriately to the results of the evaluations.
 Include guidance on evaluation of contact investigations in newly developed
recommendations/guidelines.
 Increase the capacity of state and local TB programs to conduct process and outcome
evaluations of contact investigations.
 Conduct research to identify appropriate measures of effectiveness for contact
investigations.
4. Develop systems to provide the information needed to manage contacts and evaluate
contact investigations.
 Define the elements needed for effective management of contacts and evaluation of
contact investigations.
 Develop an information system that captures these elements and promotes the
effective management of contacts of persons with infectious TB.
 Provide financial and technical support to programs to establish and use contact-
management information systems.
Objective I-F
Ensure appropriate care for patients with MDR TB, and monitor their response to
treatment and their treatment outcomes.
The resurgence of TB in the United States that started in 1985 exposed an insidious problem
for TB control: the rise in MDR TB (M. tuberculosis strains resistant to at least the two first-
line TB drugs, isoniazid and rifampin). From 1982 through 1986, only 0.5% of new TB cases
were resistant to both isoniazid and rifampin.53 By 1991, however, 3% were resistant to both
drugs, and 14% were resistant to at least one.54  Against this background of increasing numbers
of TB cases and increasing drug resistance, a dangerous new phenomenon appeared: outbreaks
of MDR TB in institutional settings. From 1990 through 1992, CDC investigated outbreaks in
eight hospitals and one correctional system and identified almost 300 cases of MDR TB. Death
rates were shockingly high – 43% to 100%. Although most cases occurred in HIV-infected
patients, several health care workers and prison guards were also stricken.
The flare-up of cases and outbreaks of MDR TB reflected serious underlying problems in the
U.S. health care infrastructure. Increasing proportions of TB cases were occurring in persons
who were homeless; were born in other countries; or had substance abuse, mental health, or
other problems, such as HIV infection, that made adherence with treatment difficult. At the
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same time that the number and complexity of TB cases were increasing, financial constraints
were resulting in cutbacks in TB control programs. As a result, health departments lacked the
resources needed to manage difficult-to-treat patients and control outbreaks.
Reversing the increase in TB and MDR TB required vigorous TB control measures and a
significant hike in public spending.14, 19, 55 With the drop in TB cases, however, there has also
come a decline in TB treatment expertise, especially MDR TB, which requires complicated
drug regimens and meticulous patient monitoring. Because the cost of treating MDR TB is so
high, many programs are unable to provide optimal treatment for affected patients. Without
renewed funding and support, MDR TB outbreaks may once again spread unchecked and exact
their heavy price.
National Action Plan to Combat Multidrug-Resistant Tuberculosis
In response to the emergence of MDR TB, a federal Task Force was convened in 1991 to
develop a national plan to combat the problem. The resulting National Action Plan to
Combat Multidrug-Resistant Tuberculosis5  identified the problems to be addressed, outlined
objectives for addressing each problem, and listed the implementation steps needed to attain
each objective. The main objectives were to 1) determine the magnitude and nature of the
MDR TB problem, 2) improve the rapidity, sensitivity, and reliability of diagnostic methods,
3) manage MDR TB patients and prevent patients with drug-susceptible TB from developing
drug-resistant disease, 4) identify persons infected with or at risk of developing MDR TB and
prevent them from developing clinically active TB, 5) minimize the risk of transmission to
patients, workers, and others in institutional settings, 6) control outbreaks, 7) increase TB
programs’ effectiveness in managing patients and preventing MDR TB, 8) enhance training,
education, and information dissemination, and 9) conduct research on more effective tools
with which to combat MDR TB.
Activities
1. Enhance the capacity of laboratories to rapidly diagnose MDR TB.
 Monitor laboratory practices and capabilities in all mycobacteriology laboratories.
 Provide funding through cooperative agreements for the upgrading of state and local
mycobacteriology laboratories as appropriate.
 Continue support of state and regional laboratories that can rapidly identify and
determine drug susceptibilities of M. tuberculosis isolates.
2. Develop networks of providers with expertise in the management of patients with
MDR TB to facilitate the referral of patients and the initiation of appropriate therapy.
 Identify providers and centers with expertise in the management of patients with
MDR TB.
 Work with selected health departments, acute-care institutions, medical schools, and
public and private providers to establish regional centers of excellence for treating
difficult-to-manage MDR TB cases.
3. Develop information systems for use in managing and monitoring the treatment outcomes
of patients with MDR TB.
 Define the elements needed for the effective management of persons with MDR TB.
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 Develop an information system that captures these elements and promotes the
effective management of persons with MDR TB.
 Provide financial and technical support to programs for establishing and using MDR
TB patient-management information systems.
Objective I-G
Ensure that health care facilities maintain infection-control precautions.
TB control programs are sources of information and consultation to the medical community on
infection-control practices that should be maintained to prevent TB transmission. During
interactions with the medical community, TB control programs should emphasize the need to
maintain a high level of suspicion for TB in evaluating patients who have TB symptoms and the
importance of early diagnosis, appropriate isolation, and prompt initiation of treatment.
Activities
1. Update and disseminate guidelines for the prevention of TB transmission in health care
facilities, including outpatient settings.
2. Promote the development of partnerships between local TB control programs and
congregate living settings (e.g., prisons, jails, homeless shelters) to ensure appropriate
infection control and prevent the transmission of TB.
 Develop local epidemiologic profiles of TB disease, including DNA fingerprinting
results, to help in the identification of groups with ongoing TB transmission.
 Identify the congregate living settings and health care providers of these high-risk
groups with whom partnerships should be established.
 Identify gaps in services to high-risk groups that would best be met by developing
partnerships to ensure infection control and prevent TB transmission in congregate
living settings.
 Emphasize partnership development in cooperative agreement announcements,
program reviews, and site visits.
 Provide assistance in developing programmatic capacity to evaluate community
partnerships.
Objective 1-H
Develop improved engineering and personal protective techniques to prevent TB
transmission.
CDC’s 1994 TB infection control guidelines presented recommendations for TB control based
on a risk assessment process that classified healthcare facilities according to various
categories of TB risk.56 A corresponding series of controls, which included administrative,
environmental, and personal protective control measures, was presented. The second level of
this hierarchy is the use of environmental controls to prevent the spread and reduce the
concentration of infectious droplet nuclei. These environmental controls include:
1) controlling the source by use of local exhaust ventilation, 2) controlling the airflow to
prevent contamination of air in areas adjacent to the source, 3) diluting and removing
contaminated air by use of general ventilation, and 4) cleaning the air by use of air filtration
alone or together with ultraviolet germicidal irradiation (UVGI). The first two levels of the
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In 2001, the TB case rate among foreign-
born persons was 26.6 per 100,000
population, a rate which is almost 9 times
higher than the rate of 3.1 per 100,000
observed among the U.S.-born population
(see graph).7 Mexico, the Philippines, and
Vietnam are the countries of origin for
nearly half of all foreign-born persons with
hierarchy (administrative and environmental controls) minimize the number of areas where
exposure to infectious TB may occur. They also reduce, but do not eliminate, the risk in the few
areas where exposure can still occur (e.g., airborne infection isolation rooms; treatment rooms
in which cough-inducing or aerosol-generating procedures are performed; autopsy rooms;
etc.). Because persons entering these areas may be exposed to M. tuberculosis, the third level
of this hierarchy of controls is the use of personal respiratory protective equipment in
situations that pose a relatively high risk for exposure.
The foundation for these activities is derived from basic research, and information gained will
be used to aid in the selection of effective engineering controls and respirators.
Activities
1. Improve engineering control measures for TB.
 Encourage and support research into development of improved engineering
techniques for preventing transmission of M. tuberculosis in high risk environments.
 Utilize computational fluid dynamics (CFD) to assess the efficacy of environmental
controls supplemental to room ventilation.
 Utilize CFD to evaluate the ability of various ventilation configurations/designs to
prevent the migration of TB from one room to another.
2. Access adequacy of personal protective equipment.
 Determine if the current user-seal checks as described by the manufacturers of N95
filtering facepiece respirators actually help to ensure an adequate fit.
 Develop a no fit-test, high-protection factor respirator performance test.
 Conduct a workplace study of how well N95 filtering facepiece respirators perform in
actual health-care settings, including determining penetration and service time
restraints.
 Conduct surveillance of how respirators are used for protection against TB in health-
care settings (types, duration of use, types and frequency of fit-tests used, and other
critical elements).
 Conduct testing of newly certified N95 respirators to determine how well each
certified respirator performs, enabling health care workers to make informed and
proper respirator selection.
Objective 1-I
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TB in the United States. Although screening with a chest radiograph, followed by acid-fast
bacilli (AFB) smears for persons with abnormal radiographs, is required for the approximately
435,000 immigrants and refugees prior to arrival in the United States annually, approximately
32 million foreign-born persons entering the United States each year are not screened for TB
(approximately 30.2 million persons with a nonimmigrant visa status; 275,000 undocumented
immigrants; and 50,000 - 1.5 million asylees). Furthermore, a number of recent studies suggest
that the screening, tracking, and notification system currently in place for immigrants and
refugees is not uniformly effective in identifying persons with active TB or ensuring
appropriate treatment and follow-up in the United States. Since the immigration status of
foreign-born persons with TB at the time of entry to the United States is not systematically
collected, it is unclear how many foreign-born persons with TB were missed at the time of
mandatory immigrant and refugee screening, were appropriately screened but developed TB
after entering the country, or were in a visa category for which no screening was required.
Information is urgently needed in order to develop strategies to reduce the incidence of TB
among the ever-increasing pool of foreign-born persons entering and residing in the United
States.
Activities
1. Conduct studies of at-entry immigration characteristics of foreign-born persons with TB,
to include
 Prospectively collect information on immigration and refugee status in the Report of
Verified Case of Tuberculosis (RVCT) form used for reporting individual case data to
CDC via the Tuberculosis Information Management System (TIMS), a surveillance and
case management software application used by TB control programs.*
 Conduct studies in various epidemiologic settings (border states, Hawaii, port cities,
and U.S. heartland areas with large numbers of immigrants and refugees) in order to
refine current estimates of risk of TB among various groups of foreign-born persons.
2. Use 2000 census data to update TB case rates for foreign-born persons overall and by
country of origin.
3. Increase information about foreign-born populations in the United States by
 Conduct contact investigation studies involving foreign-born persons.
 Modify program management reports to collect separate data for foreign-born
persons.
 Add immigration status to the RVCT.
 Build local capacity to collect and analyze data on foreign-born persons with TB that
can be used to develop local profiles.
4. Improve state and local health department capacity to develop epidemiologic profiles of
their foreign-born TB patients.
 Conduct prospective studies of immigration profiles of foreign-born persons with TB
to assist in targeting newly arrived immigrants for targeted testing and treatment of
latent TB infection.
*Any reference to future development of the RVCT (such as adding variables to it) is also part of CDC’s transition plan
to the TB program area module in the new National Electronic Disease Surveillance System (NEDSS-TB).
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5. Conduct operational research to develop better methods and procedures for identifying
and accessing high-risk border populations.
6. Improve TB case tracking of TB patients who move across the U.S.-Mexico border by
adding a binational variable to the RVCT, and by improving TB information exchange
between the United States and Mexico.
7.  Improve the sensitivity and specificity of the overseas screening algorithm:
 Conduct studies to evaluate the efficacy of overseas screening.
 Based on pilot study data, develop new algorithms (such as conducting repeat testing
in the United States, conducting all screening in the United States, adding skin test
requirements for certain immigration categories, and adding culture to the algorithm).
8. Minimize improper classification.
 Expand and enhance the existing quality assessment program training for panel
physicians who evaluate immigrant and refugee applicants outside the United States.
 Update technical instructions and forms for panel physicians.
9. Minimize loss of information from panel physicians.
 Implement a system of overseas data capture and transmission to the United States.
 Improve training of responsible Department of State staff.
 Evaluate all immigrant and refugee arrivals.
 Consolidate all arrival data at one site.
10. Improve health department notification about arrival of immigrants with radiographic
evidence of (noninfectious) TB (classification “B1”) by developing and implementing a
system of electronic TB notification.
11. Minimize delayed or omitted follow-up of class B1 immigrants by conducting
intervention studies to improve immigrants’ understanding of follow-up in the United
States.
12. Improve ongoing assessment of immigrants with radiographic evidence of TB (classes A/
B1/B2) and refugees by adding an indicator to program management reports.
13. Improve quality of civil surgeon screening for immigrants, refugees, and asylees by
 Revising technical instruction and medical forms for civil surgeons.
 Collaborating with the Immigration and Naturalization Service (INS) for civil surgeon
training.
 Assigning responsibility for civil surgeon
designation to the public health arena
(state health departments or CDC).
14. Improve communication with foreign-born
TB patients to improve their compliance with
therapy and contact investigation by hiring
field staff conversant in major foreign-born
community languages.
15. Minimize risk of treatment interruption due
to INS custody, deportation, or return to
country of origin by








 Working with INS to establish policy to ensure that TB patients in INS custody are
managed appropriately and followed to cure.
 Conducting a cohort study to assess TB outcomes.
16. Improve tracking of foreign-born persons across jurisdictions by electronic notification
of immigrants with class A/B1/B2 status to health departments.
17. Improve case surveillance along the Mexican border by
 Including TB in the CDC Division of Global Migration and Quarantine Binational
Infectious Disease Surveillance project.
 Establishing a binational TB case registry.
18. Ascertain risk of TB in foreign-born children
and children of foreign-born parents by
 Conducting special epidemiologic/risk
factor studies among immigrant/refugee
children and adoptees arriving in the
United States through collaborative
epidemiologic research projects.
 Studying TB in foreign-born children
and children of foreign-born parents to
determine why TB was not prevented.
Objective I-J
Educate the public and train health care providers to maintain excellence in TB
services.
As stated in the IOM report, as TB becomes less common, there will also be fewer individuals
with the experience and the correct knowledge to ensure that the right steps are taken and
procedures followed to control and eliminate this disease. The IOM report also states, “The
most direct solution for decreased experience is increased training.”
In an effort to identify and coordinate TB education and training resources, in 1997 the CDC
funded a project to develop a strategic plan for TB training and education. To ensure a broad
representation of issues and sectors for inclusion in the strategic plan, six work groups were
established. These work groups gathered information on specific topics and summarized their
findings in position papers that were presented at a 2-day summit held in October 1998, a
meeting that brought together experts to forecast TB training needs and efforts for the next
5 years. The recommendations from the summit were used to develop the Strategic Plan for
Tuberculosis Training and Education, which was designed to provide guidance to U.S.
agencies and organizations that conduct TB training and education for public and private sector
providers.
Countries of Birth for Foreign-born











As the result of recommendations highlighted in the Strategic Plan for Tuberculosis
Training and Education, DTBE established the TB Education and Training Network
 (TB ETN) for educators in state, big city, and territorial health departments. The goals of the
TB ETN are to
 Build, strengthen, and maintain collaboration among the key agencies and
organizations in TB education and training
 Provide a mechanism for the sharing of TB education and training resources to
avoid duplication of effort
 Develop, improve, and maintain access to TB training and education resources
 Provide updated information about TB courses and training initiatives
 Assist representatives in building education and training skills
Activities
1. The Strategic Plan for Tuberculosis Training and Education, the blueprint that
addresses the training and educational needs for TB control, should be fully funded.
2. Develop and fund programs for the education of health care providers and TB patients.
 Further the development of culturally and linguistically appropriate educational
materials for persons with or at risk for TB.
 Continue the development of an academic detailing project targeting high-risk
providers and patients with latent TB infection.
 Develop partnerships with CBOs to ensure that TB control staff are skilled in working
with their communities.
 Continue to support an educators’ network for developing and disseminating
educational materials, as well as enhancing the skills of these TB educators.
 Collaborate with training partners, such as the NIH, to expand TB education at the
academic medical center level (i.e., medical, nursing and allied health professions
schools).
3. Provide funding for projects that call for government, academic, and nongovernmental
agencies to work in collaboration with international partners to develop training and
educational materials.
 Provide training and educational technical assistance for the national TB programs in
high-burden countries.
 Participate in international advisory groups, including the Collaborative for Training
and Education in Russia and the Newly Independent States; the Training Task Force of
the Tuberculosis Coalition for Technical Assistance; the Stop TB Partnership
Advocacy and Communications Task Force; the International Union Against TB and
Lung Disease (IUATLD) TB Education Work Group; and the Partners in Health Peru
Project.
 Utilize the training and education expertise in the United States to build capacity with
global partners to systematically identify and address training and education needs in
TB control efforts.
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GOAL II: Accelerate the decline
Advance toward TB elimination through targeted testing and treatment of persons with
latent TB infection, appropriate regionalization of TB control activities, rapid
recognition of TB transmission using DNA fingerprinting methods, and rapid outbreak
response.
Unprecedented low rates of TB disease and the focal distribution of pockets of lingering
infection provide a historic opportunity to accelerate the decline in TB incidence and push
toward TB elimination. TB programs can prevent new cases by 1) reducing the reservoir of
persons with latent TB infection who will progress to active disease, 2) rapidly containing the
transmission of TB disease and infection, 3) adding regionalized TB control activities to ensure
the availability of infrastructure and expertise wherever TB cases occur, 4) characterizing
circulating TB strains using DNA fingerprinting methods to rapidly recognize and interrupt
continued TB transmission, and 5) quickly identifying, investigating, and responding to
outbreaks of TB to interrupt transmission and prevent disease.
Objective II-A
Increase the capacity of TB control programs to implement targeted testing and
treatment programs for high-risk persons with latent TB infection.
Targeted tuberculin skin testing for latent TB infection is a strategic component of TB control.
Targeted testing identifies persons at high risk for developing TB who would benefit from
treatment. Persons at increased risk for developing TB include those with recently acquired TB
infection and those with clinical conditions that are associated with an increased risk for
progression from latent infection to active disease. Targeted testing should be conducted only
among groups at high risk and should be discouraged in those at low risk. Infected persons who
are considered to be at high risk for developing active TB should be offered treatment for latent
infection regardless of age.
In CDC’s 1989 A Strategic Plan for the Elimination of Tuberculosis in the United States,1
public health agencies were assigned responsibility for detecting and treating latent TB
infection in high-risk groups. At that time, the administration of skin tests, interpretation of
test results, and intensive follow-up required to ensure adherence with treatment were believed
to be beyond the scope of private health care providers. By the mid-1990s, however, most
routine TB testing was being done outside the public health system and the participation of
other providers was recognized as essential to community efforts to prevent TB in high-risk
groups. In recommendations published in 1995, health departments were charged with helping
providers develop, implement, and evaluate locally appropriate TB screening programs.58
The key roles for TB control programs in these efforts are to identify candidates for targeted
testing and treatment (i.e., persons who, because of epidemiologic characteristics, are at high
risk for having latent TB infection or developing TB disease if infected), ensure that TB
patients have access to appropriate TB services, ensure that patients are evaluated and placed on




1. Develop and enhance the capacity of state and local TB control programs to implement
effective targeted testing and treatment programs for latent TB infection.
 Promote the development of partnerships with CBOs that provide health care services
and other health promotion activities for high-risk groups.
 Provide funding to ensure collaboration between TB control programs and CBOs.
 Conduct research to identify effective strategies and interventions that increase the
proportion of persons with latent TB infection who initiate and complete treatment.
 Develop systems to evaluate targeted testing programs for high-risk persons and to
ensure that the programs are effective in preventing the development of TB.
2. Enhance the capacity of local TB control programs to identify appropriate populations for
targeted testing.
 Provide training in epidemiologic methods and data analysis to increase the ability of
TB program staff to analyze local surveillance data.
 Identify additional sources of data (e.g., immigration patterns, HIV-seroprevalence
studies) for use in making decisions about appropriate populations for targeted
testing.
 Provide ongoing technical assistance to TB control programs to help in the
identification of appropriate high-risk groups for targeted testing.
 Promote the development of partnerships with CBOs that might have access to
persons at high risk and that might be appropriate sites for targeted testing programs.
3. Ensure that all patients with HIV infection are evaluated for latent TB infection and are
appropriately treated.
 Ensure that TB program staff are aware of the epidemiology of HIV infection, the
prevalence of TB/HIV coinfection, and the prevalence of HIV infection in persons
with active TB in their communities.
 Promote the development of partnerships with CBOs that might have access to
persons with HIV infection and that might be appropriate sites for targeted testing
programs.
 Provide funding to ensure collaboration between health departments and HIV
providers to establish targeted testing programs.
 Work with national organizations and other federal agencies to ensure that the
practice of testing for and adequately treating latent TB infection is the standard of
care for persons with HIV infection.
 Develop systems to evaluate targeted testing programs for persons with HIV infection
and to ensure that the programs are effective in preventing the development of TB in
persons with HIV infection.
4. Promote the development of partnerships between TB control programs and correctional
facilities to ensure that inmates are appropriately screened for latent TB infection and TB
disease.
 Ensure that TB control programs establish contacts in the correctional system and
promote the development of partnerships with correctional facilities to establish
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effective targeted testing programs and to follow inmates released before the
completion of treatment.
 Provide funding to ensure collaboration between health departments and correctional
health care providers for establishment of targeted testing programs.
 Work with national organizations and other federal agencies to ensure that testing for
and adequately treating latent TB infection are components of correctional health
care.
 Develop systems to evaluate targeted testing programs for persons incarcerated in
correctional facilities and to ensure the effectiveness of the programs in preventing
the development of TB in inmates.
5. Develop and implement information management systems to provide the data needed to
evaluate targeted testing programs.
 Define the elements needed for effective management of persons with latent TB
infection.
 Develop an information system that captures the elements of targeted testing and
promotes the effective management of persons with latent infection.
 Provide financial and technical support to programs to establish and use patient
information management systems for targeted testing programs.
 Establish criteria for the effectiveness of targeted testing programs, and base future
funding on those criteria.
Objective II-B
Promote the appropriate regionalization of TB control activities in high, intermediate,
and low TB-incidence areas of the United States.
As the incidence of TB declines, economies of scale dictate that the geographic focus for TB
control activities should be expanded. Ideally, patients should not have to travel to regional
centers for treatment of their disease; however, regionalization of resources for case
management, contact investigation, and outbreak investigations should be evaluated.
Activities
1. Implement the recommendations of ACET on control of TB in low-incidence areas.
2. Implement geographically defined operations research to assess the role of regional
approaches in high, intermediate, and low TB-incidence areas.
 Work with programs in low-incidence areas to develop operational research studies
and protocols.
 Implement these protocols in high-, intermediate-, and low-incidence areas.
 Publish the results of the studies, and base the development or continued support of
appropriate interventions on the results.
3. Convene a national meeting to disseminate the results of the operational research studies
and to develop recommendations for the regionalization of TB control activities.
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The National Tuberculosis Genotyping and Surveillance Network (NTGSN) was established in
1996 as a 5-year project involving seven regional genotyping laboratories and sentinel
surveillance sites in the United States. All patients from each sentinel site had M.
tuberculosis (TB) isolates genotyped using one or more molecular technologies. Routine
surveillance data were collected for each culture-positive case patient. In addition, follow-up
interviews were conducted for case-patients who had isolates that were genetically identical
to other patients in the surveillance area. Genotyping technology has been used effectively in
outbreak investigations and in identifying false-positive TB culture results that are caused by
laboratory contamination.
Objective II-C
Characterize circulating M. tuberculosis strains using DNA fingerprinting methods.
Characterization of M. tuberculosis with DNA fingerprinting is a powerful tool for
1) confirming TB cases linked by traditional epidemiologic methods, 2) identifying clusters of
patients infected with genetically related or identical strains of M. tuberculosis and
determining common sources of infections, 3) guiding contact investigations and the
appropriate use of preventive therapy, and 4) identifying laboratory cross-contamination as the
cause of misdiagnosis. When used to track the transmission of a specific strain, DNA
fingerprinting can help assess the effectiveness of TB control programs — a particularly useful
methodology for areas with low TB incidence as the United States approaches TB elimination.
Activities
1. Use DNA fingerprinting to strengthen TB control efforts.
 Create Regional Centers of DNA Fingerprinting Excellence that can provide DNA
fingerprinting for all new isolates of M. tuberculosis.
 Establish a DNA Fingerprinting Training Program to build laboratory, epidemiologic,
and analytic capacity to assess and promote fingerprinting standards and practices,
including newer DNA fingerprinting approaches.
 Establish a National DNA Fingerprinting Registry and Surveillance System to
facilitate the identification of TB outbreaks that cross state lines.
 Develop local capacity in the use of DNA fingerprinting to identify laboratory
misdiagnoses of TB and thereby reduce the number of persons who are
inappropriately treated for TB.
2. Use DNA fingerprinting to increase the understanding of TB epidemiology and provide
the scientific foundation for improved interventions to eliminate TB.
 Study geographic and temporal variability in genotypes to better understand the natural
history of M. tuberculosis strains currently in circulation in the United States
(especially MDR strains, strains that cause relapses, and geographically widespread
strains) and to evaluate the impact of interventions locally and regionally.
 Identify and investigate unrecognized transmission of TB in groups at high risk
(e.g., HIV-infected persons, residents of correctional and long-term–care facilities,
migrant farm workers, homeless persons).
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 Identify and investigate unusual and difficult-to-recognize settings where TB
transmission has occurred, especially in areas that have achieved low TB incidence.
 Study the frequency of reinfection, relapse, and infections with multiple strains of
M. tuberculosis.
 Use DNA fingerprinting to monitor progress toward eliminating TB transmission.
3. Develop and evaluate new DNA fingerprinting tools.
 Evaluate newly developed DNA fingerprinting technologies (e.g., spoligotyping,
minisatellite-based typing systems, fluorescent amplified fragment-length
polymorphism).
 Develop novel strain typing and DNA fingerprinting approaches.
 Develop and evaluate fingerprinting methods or strategies that can provide rapid strain
typing for real-time application in TB control efforts.
Objective II-D
Develop national, state, and local capacity to respond to outbreaks of TB.
When TB is very common, clusters of cases caused by recent transmission blend into the
generally high morbidity. However, when TB is less common, even small case clusters are very
noticeable and are considered to be “outbreaks.” In the United States, several interrelated
factors are converging to make TB case clusters more prominent and troublesome. First,
M. tuberculosis transmission is now uncommon, and most members of the population have not
been infected. Therefore, a burst of transmission causes a disturbance that stands out from the
low background level. At the same time, however, the low background level has led to reduced
personnel resources and thus limited our capacity to find and cure TB and to investigate
contacts. Many health care providers now lack familiarity with TB, have difficulty diagnosing it,
and are unaware of current treatments. The combination of delayed case detection, enhanced
opportunities for transmission to susceptible contacts, and reduced response capacity yields
sporadic “TB outbreaks.”
Each TB outbreak is a setback for TB elimination. As the incidence of TB declines, the
identification of and response to outbreaks will become a more important component of TB
control. Responding to these outbreaks will require careful planning, marshaling of resources,
development and maintenance of expertise, and development and use of interventions to
interrupt transmission and prevent TB disease.
Activities
1. Implement and evaluate CDC’s outbreak response plan.
 Conduct a pilot study on implementation of the outbreak response plan.
 Evaluate the plan, and identify needed improvements.
 Finalize the plan based on results of the evaluation.
 Implement the plan.
 Devise mechanisms for ongoing evaluations and revisions.
2. Provide guidelines, technical assistance, and templates to help state and local TB control
programs develop and implement their own outbreak response plans.
3. Enhance the capacity of CDC and state and local TB control partners to respond rapidly to
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outbreaks, conduct appropriate investigations, and implement necessary programmatic
activities to interrupt TB transmission.
 Ensure that CDC maintains appropriate numbers of trained scientific staff to help
states and localities investigate TB outbreaks.
 Ensure that CDC maintains appropriate numbers of trained program staff both in the
field and at headquarters to respond appropriately to TB outbreaks and to provide
technical assistance as needed to state and local TB programs.
 Through training and funding, develop the capacity of state and local TB programs to
respond rapidly and appropriately to TB outbreaks.
4. Evaluate the cost and impact of outbreak investigations and subsequent programmatic
interventions.
 Define the data elements needed to evaluate the cost and impact of outbreak
investigations and interventions.
 Develop data management systems to capture these elements.
 Conduct a comprehensive evaluation of outbreak responses by CDC, and help state
and local programs develop evaluations of their responses to outbreaks.
GOAL III: Develop new tools
Develop and assess new tools for the diagnosis, treatment, and prevention of TB.
Improving the application of current tools can enhance TB prevention and control efforts, but
achieving the goal of TB elimination will require more. The United States needs to develop and
then quickly and appropriately implement new technology to accelerate the decline in TB
morbidity and make TB elimination a reality. In the long run, an effective vaccine would have
the greatest impact on the ability to control and ultimately eliminate TB. However, new tools
are also needed to improve the accuracy and speed of TB diagnosis and the effectiveness of TB
treatment. The nation therefore needs to expand its research program, capitalizing on past
investments and progress and creating critically needed new tools for diagnosing, treating, and
preventing TB.
Objective III-A
Develop a coordinated plan for TB research.
NIH and CDC have the lead in federally funded research on TB. Other agencies involved in TB
research include FDA, HRSA, the Veterans Administration (VA), the Occupational Safety and
Health Administration (OSHA), the Indian Health Service (IHS), and the Department of
Defense (DoD). Despite the involvement of each of these agencies in basic and operational
research on TB, the nation lacks a clearly articulated research strategy that addresses each
group’s responsibilities and contributions. A coordinated research plan is needed to maximize
efficiency, ensure attention to highest priority activities, and avoid duplication of efforts. In
part to address this need and to move operational research forward, in 2001 the CDC
established the Tuberculosis Epidemiologic Studies Consortium (TBESC). TBESC is
composed of 22 collaborative research groups, each existing as a formal partnership between
an academic institution and a state or metropolitan TB control program.
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Activities
1. Achieve consensus that a coordinated research plan is needed.
2. Convene a meeting of representatives of interested public sector agencies and private
companies to develop a prioritized list of research activities and to assign lead
responsibilities for these activities.
3. Disseminate the research plan.
Objective III-B
Develop new methods to diagnose persons with latent TB infection and to identify
infected persons who are at high risk of developing active TB.
Achieving the goal of TB elimination will require increased attention to persons with latent TB
infection and those at greatest risk of developing active TB.8, 11 Identifying and treating these
persons can prevent the onset of active TB and interrupt the spread of disease. Until recently,
skin testing with purified protein derivative (PPD) tuberculin was the only practical way to
detect latent TB infection. In the United States, the tuberculin skin test (TST) is used as an
initial screening test for both latent infection and active TB; a positive TST indicates an
increased risk of subsequently developing, or currently having, active TB.59 Despite its
widespread use and a large body of data on its standardization, the TST has several elemental
shortcomings that limit its usefulness:
 Persons infected with nontuberculous (environmental) mycobacteria and those
previously vaccinated with BCG (an anti-TB vaccine used in many other countries) can
test falsely positive.
 Many conditions, most notably HIV-associated immunosuppression, can blunt the
response to tuberculin and lead to false-negative results.
 The lack of standardization in administering and reading the test can affect the
results.59
In “Comparison of a Whole-blood Interferon
Assay with Tuberculin Skin Testing for
Detecting Latent Mycobacterium
tuberculosis Infection,” the authors conclude
that the interferon assay was comparable with
the TST in its ability to detect latent infection,
was less affected by BCG vaccination, was
able to discriminate responses due to
nontuberculous mycobacteria, and avoided the
variability and subjectivity associated with
placing and reading TSTs.33
 A promising advance may address at least one
of these limitations. The discovery of the role
of T-lymphocytes and gamma-interferon in the
immune process has led to the development of
a blood test for cell-mediated immune
reactivity to M. tuberculosis. An initial
assessment of this test suggests that it may be
useful in distinguishing persons with positive
TST reactions due to BCG vaccination and
sensitization by environmental mycobacteria.
TB control is also hampered by the inability to reliably identify infected persons who are most
likely to develop active TB.11 Factors related to the progression from latent infection to active
TB include 1) the intensity of the initial exposure, 2) recent rather than remote infection, and
3) medical conditions such as HIV infection that weaken immunity. A better understanding of
the immunologic and genetic factors associated with the human response to TB infection is
needed to predict which persons with latent infection are at highest risk of progressing to
active disease. This information is also needed to guide the development of an optimal TB
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Activities
In coordination with other federal agencies
1. Continue the development and assessment of cytokine-based assays for the diagnosis of
latent TB infection. Continue support for studies of more specific mycobacterial antigens
that might enhance diagnostic accuracy.
2. Provide continued support for the development of specific skin-test antigens to improve
the diagnosis of latent TB infection, and conduct studies of the usefulness of purified and
specific antigens for TB skin testing. The immunologic response measured by skin testing
differs from that assessed by cytokine assays, and it is possible that a combination of skin
testing and cytokine assays will be able to better identify persons with latent infection
who are at highest risk of progression to active TB.
3. Through the TBESC, support and expand epidemiologic studies to identify immunologic
and genetic markers that are associated with protection against TB and susceptibility to
progression from latent infection to active disease.
4. Develop and refine new molecular, biochemical, and immunologic methods for rapid,
accurate, and cost-effective diagnosis of active TB and drug-resistant TB, including
technologies for use in low-income countries.
Objective III-C
Assess new drugs to improve TB treatment and prevention.
Until the FDA approval of rifapentine in 1998, it had been more than 25 years since the
introduction of a novel compound for the treatment of TB. Despite many calls over the past two
decades for the development of new anti-TB drugs, the pharmaceutical industry has, with few
exceptions, indicated little interest in undertaking work in this area. One factor impeding this
pursuit is the erroneous perception that current drugs are adequate for the control of TB. In
fact, new TB drugs are urgently needed to 1) improve current treatment regimens by shortening
the duration of treatment and/or offering more widely spaced intermittent treatment;
2) improve the treatment of MDR TB; and 3) provide more effective treatment for latent TB
infection.60
Although the current TB treatment regimens are highly effective, they are far from ideal. The
main drawback is the prolonged duration of treatment; currently, at least 6 months of treatment
is required. Not only is treatment lengthy, but the regimens are complex; the initial part of
therapy requires taking four different medications. Although rates of serious adverse reactions
are low, therapy can also be associated with unpleasant side effects.
To be effective, treatment must be continued to completion. The prolonged TB drug regimens
are associated with high rates of nonadherence and subsequent increased mortality and creation
of chronic drug-resistant cases.61 Development of drug resistance is far more likely when
treatment is not supervised and when recommended regimens are not used. To ensure that
patients take their medicine correctly, DOT is generally advised. New drugs that could be
vaccine. Involving private sector biotechnology and pharmaceutical companies in collaborative
endeavors will be increasingly important.
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administered in shorter, simpler regimens would have the greatest impact on the TB problem in
the near term.
As rates of MDR TB increase in many countries,44, 62 finding alternative drugs to improve the
treatment of patients with drug-resistant TB is also a high priority. Patients with MDR TB must
be treated with a combination of “second-line” drugs that are not only more expensive but also
more toxic and less effective than the standard medications.63
The final impetus for the development of new TB drugs is to improve the treatment of latent
infection. Among the approximately 2 billion persons worldwide with latent TB infection, an
estimated 100 million to 200 million will develop active disease. In the United States and
several other low-incidence countries, isoniazid has been used for the treatment of latent
infection in persons at greatest risk of disease progression. Isoniazid has also been shown to be
effective in preventing the development of TB in TB-HIV coinfected persons, and WHO has
recommended the use of isoniazid in such persons.64 Because isoniazid therapy has significant
limitations, however, new drugs to improve the treatment of latent infection are needed to
eliminate TB from low-incidence countries.11
Historically, CDC has been the lead U.S. agency for the conduct of clinical trials to evaluate TB
treatments. From 1993 to 1994, CDC contracted with investigators at academic medical
centers, health departments, and VA hospitals to conduct U.S. Public Health Service (USPHS)
Study 22, a randomized trial to evaluate rifapentine. The findings demonstrated the efficacy of
once-weekly treatment for selected TB patients and are being used to update TB treatment
recommendations being issued jointly by CDC and ATS.
From 1997 to 1998, CDC worked with the same group to establish the TBTC, an investigator-
driven program modeled on the NIH-supported Community Program for Clinical Research in
AIDS (CPCRA). The TBTC is evaluating rifapentine and other drugs to improve and shorten TB
treatment and has embarked on a study of treatment of latent TB infection with a once-weekly,
12-dose regimen of rifapentine and isoniazid.
Globally, several countries with high rates of TB (e.g., Kenya, Uganda, South Africa, India,
Brazil) also have considerable capacity to conduct clinical trials. In the past, CDC has
supported TB research in several of these countries, and investigators at many sites are
interested in collaborating on both treatment and prevention studies. Such studies would greatly
facilitate the development of new treatment and prevention drugs that are needed not only in the
United States and other industrialized countries but also in high-burden countries where the TB
epidemic is most severe.
Activities
1. Continue and enhance support for the TBTC. Provide needed resources to both increase
capacity at the research sites and recruit new sites, and collaborate with interested
partners (within and outside the United States), so that ongoing and additional studies can
be completed expeditiously.
2. Encourage enhanced private-sector support and public- or private-sector collaboration for
the development of new, effective drugs and other therapeutic interventions to improve
the treatment of both active TB and latent TB infection.
3. Work with interested partners to develop and support an international TB trials network.
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Objective III-D
Develop a new and effective TB vaccine.
A concerted and sustained national effort to develop an effective new TB vaccine is crucial to
eliminating TB from the United States and significantly reducing the global burden of TB.
Vaccine development will require the sustained commitment of both private and public sector
funds over several decades to support intramural and extramural research. Much of this work
will fall within the mission of NIH, but CDC, as well as other federal agencies, have important
roles to play.65
The Global Alliance for TB Drug Development is an international nonprofit organization
whose vision is the provision of new medicines with equitable access for the improved
treatment of TB. Its mission is to accelerate the discovery and/or development of cost-
effective, affordable new TB drugs that will shorten or simplify treatment, provide a more
effective treatment of multidrug-resistant TB, and improve the treatment of latent TB
infection. The Global Alliance seeks to have a new drug that achieves these improvements
registered by 2010. The Global Alliance is one of a new breed of public-private partnerships
that pursue a social mission by drawing upon best practices, expertise, and resources from
both the public and private sectors.
Activities
Assist relevant federal agencies and other national and international partners to-
1. Establish consensus among public and private funding agencies, vaccine manufacturers,
and professional organizations that a new TB vaccine is an urgent public health priority.
Identify a long-term commitment of private- and public-sector funds to support vaccine
research.
2. Develop a comprehensive vaccine development strategy that builds on the Blueprint for
Tuberculosis Vaccine Development.39 The strategy should specify
 Desirable characteristics of a new vaccine.
 Action steps for vaccine development.
 Roles and responsibilities of the public sector, industry, and academia.
 Projected time line.
 Estimate of resource needs.
3. Increase biomedical research to define host factors for TB protection and susceptibility.
 Expand basic research efforts to define 1) host factors that may protect against both
the establishment of infection and the development of TB disease, and 2) the
properties of the tubercle bacillus that permit it to survive years after the
establishment of infection. Organize studies with hypothesis-generating protocols
linking epidemiology, human immune status and response, and other physiological
responses to TB infection and disease and the bacteriology of infecting organisms,
taking advantage of the best available science, incident cases, contacts, and laboratory
facilities.
 Expand studies to determine the immunologic and genetic markers related to
protection and progression from latent infection to active disease.
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 Determine correlates of protection for trial participants to facilitate vaccine trials.
4. Develop new animal models for assessing vaccine efficacy.
5. Increase collaborations between the private and public sectors for implementation of
clinical vaccine trials.
 Increase collaboration among CDC, FDA, and NIH5 through regular communications
of the Federal TB Task Force.
 Develop and foster relationships with international organizations (e.g., WHO),
funding agencies (e.g., U.S. Agency for International Development [USAID], World
Bank, private foundations), and vaccine manufacturers.
 Convene a working group with representatives from these agencies to develop
protocols for fieldtesting of candidate vaccines.
 Identify vaccine trial sites in the United States and in high-incidence countries, and
make immediate preparations for clinical testing. Avoid committing major funding
expenditures for vaccine testing sites too far in advance of the availability of
minimally suitable vaccine candidates.
 Increase dialogue among the USPHS, FDA, WHO, USAID, vaccine manufacturers, and
other interested parties (e.g., public health and medical communities, private
foundations).
 Seek collaborations domestically and internationally with public and private partners
to advance vaccine development. Work with sister agencies and other national and
international partners to enhance the activities of established groups that provide
guidance and oversight on TB vaccine development.
Objective III-E
Develop and implement a program of research on behavioral factors related to TB
treatment and prevention.
Despite the efforts of national, state, and local TB programs, nonadherence with prescribed
treatment remains a major barrier to TB elimination.11 An additional weapon in the TB
elimination arsenal is research to 1) understand behavioral factors related to TB treatment and
prevention in patients and health care providers, and 2) design and implement methods for
improving adherence with TB treatment. The IOM charged CDC with developing and
implementing a behavioral and social science research agenda to promote this understanding as
a needed “new tool” for achieving TB elimination.
The last national effort to assess the state of TB-related behavioral and social research was a
conference conducted in 1994.66 The proceedings generated many ideas but produced no
structure for planning and directing research. In the interim, much research has been conducted,
and many promising practices and effective interventions have been implemented in state and
local TB programs. Data and findings reside, however, with individual researchers and program
staff. There is also a wealth of untapped but potentially transferable research on other health
problems characterized by similar adherence issues. By comprehensively and critically




1. Collect information on current TB-related behavioral research.
 Review published and unpublished materials to identify effective behavioral initiatives
and best practices in the 68 CDC-funded TB control programs.
 Select promising practices and initiatives, and conduct follow-up interviews to
describe and identify the replicable aspects of each.
2. Convene a meeting of experts to develop a research agenda.
 Include a range of stakeholders, including researchers, program staff, CBOs, and
policy makers.
 Charge the participants with reviewing the status of behavioral and social science
research as it relates to TB control.
 Structure the meeting to identify existing and needed resources and information, set
goals and objectives for a research agenda, and develop a plan of action for conducting
behavioral and social science research related to TB control and prevention.
 Establish working groups to review progress and revise and advance the agenda.
Objective III-F
Rapidly transfer findings from research studies into practice.
Successful implementation of new technologies will require education and training to produce
changes in the practices of health care providers.
Activities
 1. Create messages, materials, and programs for health care providers to ensure their
understanding and application of new developments in TB prevention and control.
2. Base the messages, materials, and programs on established communication and behavior-
change theories and models.
3. Develop a communications/media strategy to ensure efficient transfer of new
technologies into practice.
GOAL IV: Increase involvement in global efforts
Increase U.S. involvement in international TB control activities to reduce the global
burden of TB.
TB cannot be eliminated in the United States without a considerable reduction in the global
burden of TB.9 In 2001, approximately 50% of newly diagnosed U.S. TB patients were born
outside the United States.7 Most of these patients acquired their TB infections in countries
such as Mexico, the Philippines, Vietnam, India, China, and Korea but did not have clinical
disease when they entered the United States. Subsequently, for reasons not sufficiently
understood, their immune systems were unable to keep the infections in check and they
developed active TB. Within the next several years, it is expected that more than half of the new
TB patients diagnosed each year in the United States will be foreign-born persons.
The global community is fighting TB on several fronts. Based on the pioneering work of the
IUATLD, WHO has developed a specific strategy for TB control in low-income countries. The
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strategy, called “directly observed treatment, short-course” (DOTS), combines five elements:
1) the political commitment of the government to support TB control programs,
2) bacteriologically-based diagnosis, with AFB-smear microscopy of sputum specimens of
patients with symptoms of TB, 3) standardized treatment with rifampin-based (short-course)
regimens given under direct supervision, 4) a reliable supply of quality drugs and diagnostic
supplies, and 5) individualized reporting of treatment outcome coupled with program
monitoring and supervision. DOTS coverage has expanded greatly during the past decade, but
inadequacies in diagnostic and treatment tools limited its easy applicability. A global
partnership, Stop TB was created to help coordinate the efforts of governments,
nongovernmental agencies, and donor agencies in global TB control. Working through the Stop
TB Partnership, CDC has contributed to DOTS expansion and also addressed the recalcitrant
problems of MDR TB and HIV-associated TB.
Although MDR TB has come under control in the United States, it appears to be a much more
serious problem internationally. In 1999, the estimated proportion of multidrug resistance in
new TB patients was 1.6% in the United States but reached as high as 10% in Latvia and Russia
(see graph). Rates of TB and drug-resistant TB have been increasing at an alarming rate in
Russia, fueled by 1) lack of continuous access to quality drugs, 2) the country’s inability to
support the TB diagnosis and treatment infrastructure, 3) high levels of TB transmission in
prisons, 4) limited TB control policies and reluctance to adopt the WHO-recommended DOTS
strategy, and 5) increasing levels of HIV infection.
At the request of the USAID mission in Moscow, WHO, CDC, and USAID are implementing
DOTS programs in the Orel and Vladimir oblasts (territorial administrative divisions) and
strengthening the DOTS program started by WHO in Ivanovo oblast in 1995. As part of the
implementation of DOTS-Plus (WHO’s strategy for managing MDR TB in low-resource
settings) in the Ivanovo oblast, CDC 1) developed a diagnostic and treatment protocol that has
become the basis for the Russian DOTS programs, 2) posted CDC public health advisors to
3-month temporary assignments to help implement DOTS and DOTS-Plus strategies,
3) helped establish a national TB surveillance system, and 4) conducted epidemiologic studies
of risk factors for development of MDR TB. CDC has also provided laboratory training, quality
assurance for drug sensitivity testing, and consultation. As a result of these actions, cure rates
in Ivanovo oblast have risen from 61% to 75%; in the initial cohort in Orel, the cure rate was
83%.
CDC has also been involved in activities to strengthen TB laboratory services in low-income
countries. Throughout much of the world AFB microscopy is the basis for diagnosis and
control of TB, but there is currently no practical guidance for national programs in monitoring
and promoting quality testing at the clinic level. CDC and its Stop TB partners are developing
international guidelines on national external quality assessment programs for microscopy. CDC
has also developed several products that are focused on providing training to the laboratory
technician performing AFB microscopy at the local level in middle- and low-income countries.
CDC is also engaged in WHO-sponsored international efforts to evaluate the effectiveness of
treatment strategies for MDR TB in low-resource settings and to conduct large-scale purchases
of MDR TB drugs that will lower prices to a fraction of current levels. CDC is a charter
member of an MDR TB working group and serves as one of five international agencies that
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review MDR TB treatment protocols submitted by national TB programs for potential
participation in WHO’s MDR TB treatment network.
Efforts to address TB-HIV coinfection include the implementation of the BOTUSA Project in
Botswana. In 1995, at the invitation of the Ministry of Health, CDC established a TB-HIV field
site in Botswana, a country with high HIV prevalence and high TB case rates. The field site is
collaborating with the Botswana Ministry of Health, WHO, and other countries on the
provision of TB preventive therapy to persons with HIV infection and the development of
methods to improve TB diagnosis in low-resource settings. The BOTUSA site serves as a base
for regional USAID-funded TB activities throughout southern Africa, including an assessment
of drug quality and the implementation of a computer-based TB surveillance system. Research
projects have addressed 1) causes of illness in patients with suspected TB whose initial
diagnostic evaluation was negative, 2) use of molecular epidemiology techniques to identify
risk factors for TB transmission, 3) absorption of TB drugs in patients coinfected with TB and
HIV, 4) TB drug resistance, 5) patients’ knowledge and attitudes about HIV and TB testing,
6) acceptability of preventive therapy, and 7) TB patients’ risk behaviors for HIV transmission.
BOTUSA is working with the national AIDS and TB programs to explore the use of preventive
therapy postnatally in HIV-positive women and to identify other populations for TB preventive
therapy.
Objective IV-A
In collaboration with WHO and other international partners, provide leadership in
public health advocacy for TB prevention and control.
Activities
1. Increase collaboration with the Stop TB Partnership at both the global and regional levels.
2. Working with the USAID-funded TB Technical Advisors Consortium, increase the pool of
skilled persons who can provide technical assistance to TB control programs.
3. Support the educational programs of IUATLD.
4. Contribute to the development of technical guidelines and recommendations through
participation on international working groups (e.g., Green Light Committee, WHO
Scientific and Technical Group for TB, Regional WHO Advisory Committees).
5. Provide technical assistance to USAID for activities related to TB control.
6. Coordinate with NIH in international TB control and research.
Objective IV-B
Provide technical support and build capacity for implementation of DOTS, especially in
those countries that contribute significantly to the U.S. TB burden.
1. Contribute technical support and capacity-building assistance to strengthen
epidemiologically-based DOTS implementation in 3 to 5 countries from which a high
volume of U.S. TB cases originate and in several of the other 22 high-TB burden countries
identified by WHO.
 Conduct operational studies to enhance the implementation of DOTS.
 Improve TB surveillance.
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 Provide training in program management, epidemiologic methods, and operations
research.
 Assist in program reviews (WHO, IUATLD, USAID).
2. In collaboration with the Stop TB Partnership, develop technical guidelines and training
products that strengthen laboratory services in high-burden countries.
Objective IV-C
In collaboration with WHO and other partners, develop models for the diagnosis and
treatment of MDR TB in countries with high rates of drug resistance.
1. Expand and enhance the Latvian model center (see page 50).
2. Provide assistance to the MDR TB project in Peru funded by the Bill and Melinda Gates
Foundation.
3. Implement DOTS-Plus in Ivanovo, Russia.
Objective IV-D
Provide technical, programmatic, and research support aimed at reducing the incidence
of TB as an opportunistic disease in high HIV-burden countries.
1. Through collaboration with CDC’s Global AIDS Program (GAP), provide technical
assistance for TB surveillance in countries with high rates of HIV-associated TB.
2. Through collaboration with GAP, provide technical assistance for enhanced TB laboratory
capability in countries with high rates of HIV-associated TB.
3. Through BOTUSA and other GAP-supported programs, conduct operational research to
improve the diagnosis and treatment of HIV-associated TB.
4. Conduct large-scale feasibility studies of various regimens for the treatment of latent TB
infection in HIV-infected persons.
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Center of Excellence for the Management of MDR TB in the Baltics
Latvia has one of the highest rates of drug resistance in the world. In 1999, 10% of new TB
patients had MDR TB; this compares with 1.6% in the United States and <1% in most
African countries. The high rates of MDR TB are attributed to poor treatment programs and
drug shortages that occurred in the early 1990s after the fall of the Soviet Union.
In 1999, with fiscal support from the U.S. Department of State, CDC and USAID signed a
Memorandum of Agreement to 1) develop a Center of Excellence for the diagnosis and
management of MDR TB in Latvia, and 2) disseminate lessons learned to Estonia, Lithuania,
and other republics of the former Soviet Union where TB control efforts have been
compromised by drug resistance. The Center was designed to develop local expertise and
facilities that can provide world-class diagnosis and treatment of MDR TB and to use locally
trained experts and facilities to train persons from other countries in the region. The project
builds on a foundation of basic TB and MDR TB treatment programs that are being supported
by the Latvian government with financial and technical support from the World Bank and the
Nordic countries.
Since the signing of the agreement, the Center has made substantial progress in three focus
areas:
1) building expertise among Latvian physicians by strengthening clinical practice and
management,
2) designing and implementing infection-control measures, and
3) organizing MDR TB training for physicians from elsewhere in the region.
In September 1999, the Center initiated a study of risk factors for primary and acquired MDR
TB; findings will facilitate early targeting of patients with likely MDR TB for more rapid
diagnosis and possible presumptive treatment. The training component began in March 2000
with a course for Latvian physicians who manage MDR TB patients. By use of
videoconferencing, the Center also conducts regular meetings in which Latvian physicians
present and discuss difficult management issues with U.S.-based experts. Finally, the Center
has started development of an MDR TB data management system that will facilitate case
management and treatment outcome studies, the results of which can be used to improve
clinical practice. The data system can also serve as a model for a WHO consortium of
countries conducting pilot projects in MDR TB management.
Infection-control efforts are designed to respond to evidence of ongoing transmission of MDR
TB to staff and patients. The Center is developing an infection-control plan that includes the
installation of air-cleaning equipment. A plan to ensure more rapid laboratory diagnosis of drug
resistance is also being developed so that MDR TB patients can be segregated from other
patients and treated more quickly.
Regional training, the final component of the project, began in January 2001 with the training
of the first group of physicians from Russia. The 3-week course, which was taught by CDC’s
Latvian collaborators in Russian, was an expanded version of the initial MDR TB course
staged for Latvian physicians in March 2000 and included extensive opportunities for
discussion of case management.
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Initiative/Global AIDS Program
In 2000, the U.S. government launched the Leadership and Investment in Fighting an
Epidemic (LIFE) initiative with a $100 million increase in U.S. support to 14 countries in
Africa and India. CDC received $35 million of the initial funds and through its newly formed
Global AIDS Program is working closely with USAID to implement this initiative. CDC’s
objectives are to 1) reduce HIV transmission through primary prevention of sexual, mother-to-
child, and bloodborne transmission, 2) develop programs to improve community and home-
based care and treatment of HIV infection, other sexually transmitted infections, and
opportunistic infections, and 3) strengthen the capacity of countries to collect and use
surveillance data and to manage national HIV/AIDS programs. Improving TB prevention and
control efforts is an important component of the project, and CDC staff have been involved in
1) developing project blueprints consisting of “best practices,” 2) participating in site visits, and
3) convening experts to provide input into the selection of countries for initial efforts and the
proposed content for country-specific projects; initial TB efforts have focused on six
countries.
GOAL V: Mobilize and sustain support
Mobilize and sustain support for TB elimination by engaging policy and opinion
leaders, health care providers, affected communities, and the public. Implement a
comprehensive health communication campaign that supports TB elimination and
ensures the development and delivery of effective TB elimination messages. Improve
communication efforts through consistent monitoring and evaluation of the plan’s
methods and strategies.
A comprehensive CDC health communication effort will develop momentum for TB
elimination at the national and local levels. At the national level, the communication plan will
include the use of news media and outreach to national organizational partners. At the local
level, CDC messages and strategies should be an integral component of a data-driven,
community-specific plan to foster strong linkages among health departments, community
leaders, organizational partners, and the affected community. CDC’s communication efforts
will be national in scope, but strategies will vary according to TB morbidity levels in a
particular area. The use of existing surveillance data will be a key determinant in defining
specific target audiences and developing communication strategies to reach the targeted groups
of the general public.
Objective V-A
Develop and implement a health communications effort focusing on the achievable goal
of eliminating TB.
To secure needed resources and support, all partners — policy makers, leaders from affected
communities, clinical and public health organizations, and the general public — must support
and advocate for TB elimination. Policy makers must understand the importance of and need




1. Develop and implement a national health comunication campaign to raise the awareness of
policy makers, health care providers, and the public about the ongoing toll of TB and to
create support for elimination efforts. Elements of this campaign include but are not
limited to the following:
 Identify key messages to communicate to these specific audiences.
 Identify and train national spokespersons. Include representatives from CDC, affected
states and communities, and key organizational partners.
 Create sustained media outreach. Working with national and local TB program staff,
plan a calendar of newsworthy events, including data releases, journal articles,
conferences, program milestones, grant awards, and other items of interest. Focus
outreach on major national print, electronic, and news media outlets as well as outlets
associated with affected areas and high-risk populations.
 Develop features highlighting local success stories and outbreak responses. Examine
how these efforts affect individuals and communities and can help prevent the spread
of TB.
 Explore how local outbreak responses can support national communication
objectives. Implement protocols for obtaining outbreak information from local health
jurisdictions and funneling the information to neighboring and other jurisdictions and
to organizational partners, policy makers, and community groups.
2. Encourage support for new diagnostic, treatment, and prevention methods by informing
TB prevention leaders and policy makers about progress in TB elimination using local data
and the resources needed to ensure continued progress.
 Develop routine and coordinated communication with state health officers, TB
prevention leaders, and other policy makers on TB morbidity in their communities.
 Create or enhance mechanisms to disseminate TB information rapidly. Tailor the data
presented and method of communication to the needs of target audiences.
 Create a systematic, yearly plan to highlight TB elimination activities at conferences,
meetings, and events attended by policy makers and TB prevention leaders.
3. Develop communication partnerships with national organizations.
 With consultation from members of the National Coalition to Eliminate Tuberculosis
(NCET), create a list of the top ten national organizational partners. Selection criteria
might include credibility with target audiences, organizational reach to target
audiences, and ability to mobilize organizational networks.
 With consultation from the American Lung Association (ALA), identify key leaders
from the top ten organizational partners. Initiate contact, and assess each group’s
availability to work on the communication campaign.
 Work with each local and national organization to customize program messages and
develop initiatives at the community level. Obtain input from partner organizations
during the development, implementation, and evaluation of communication activities.
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Objective V-B
Help communities foster nontraditional, multisectoral, public-private partnerships to
improve the effectiveness of their communications activities, with particular attention
to culturally appropriate materials.
TB elimination will require significant community buy-in, support, and involvement. State and
local health departments must build support in affected communities; develop mechanisms for
ongoing communication with organizational staff, community leaders, and policy makers; and
encourage the community to join the elimination effort. Community groups can help define
local needs and assets and specify how needs can be appropriately and effectively addressed
and how assets can be deployed. Community partners can facilitate the implementation of rapid
outbreak response, provision of clinical and laboratory services, and enhanced health
promotion interventions. Credible community leaders can deliver messages and distribute
materials that promote health care–seeking behavior in at-risk populations.
Activities
1. Develop consistent and routine communication channels for sharing TB-related
information with state and local health departments.
 Sustain existing communication systems, and develop additional systems
(e.g., listservs, broadcast fax, broadcast email) as needed to facilitate the receipt and
use of TB-related information by state and local health departments.
 Provide health departments with access to TB-related health communication and
community participation materials.
2. Create unifying TB elimination messages and a partnership-building tool kit for states.
 Conduct formative research with community representatives to develop community
involvement messages.
 Develop and evaluate a prototype partnership-building tool kit, guided by qualitative
research and pretest findings.
3. Support state and local health departments in their efforts to engage community
representatives in TB elimination activities.
 Create mechanisms for dialogue among community representatives, health
departments, and CDC staff (e.g., on-site consultations, listservs, discussions at
regional meetings).
 Conduct research on models for conceptualizing, planning, and implementing
appropriate community input mechanisms (e.g., town hall meetings). Examine the use
or adaptation of the popular opinion leader HIV/AIDS prevention intervention package
for TB elimination. Host small meetings to learn what works in states, and
disseminate the findings.
 Create materials (e.g., slide shows, fact sheets, brochures) in collaboration with
health departments and community leaders to inform community groups, managed-
care organizations, and provider groups about the TB elimination effort.
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4. Equip community representatives with local data and tested materials to help them
develop interventions and materials that promote TB awareness among at-risk persons.
 Conduct formative behavioral research with at-risk persons to determine their
knowledge, attitudes, and beliefs about TB and TB testing. (See IIB.)
 Review and incorporate relevant information gleaned from World TB Day efforts.
 Develop and implement a health communication training/technical assistance strategy
for community representatives. Design training courses to enhance health
communication capacity in local areas beyond the TB elimination effort.
Objective V-C
Support the development of state- or area-specific TB elimination plans that contain
communications activities to build public support for TB elimination.
Activities
1. Provide ongoing technical assistance to state health officers, TB controllers, and other
leaders in developing TB elimination strategies, approaches, and plans.
 Use existing surveillance data to identify successful programs and program
challenges.
 Use the information gathered about successful TB elimination activities to develop
tools (e.g., best-practices information, newsletter articles, op-eds) for other states.
 Host a meeting or session at the National TB Controllers Workshop, American Public
Health Association (APHA) annual meeting, and other key national conferences to
showcase best practices and lessons learned and to disseminate tools for replication.
2. Conduct “Mobilizing for TB Elimination” workshops for state TB controllers and their
partners to train them in the development of state- or area-specific TB elimination plans
that contain communications activities to build public support for TB elimination.
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Stages in the Health Communication Process
All activities undertaken as part of the CDC communications campaign will be planned and
conducted according to the following Stages in the Health Communication Process67:
Stage 1: Planning and Selecting a Strategy
 What do we know about the health problem?
 Who are the target audiences? What is known about them?
 What are the program goals?
 What measurable objectives can be established to define success?
 What are the messages?
 How will the initiative be evaluated?
Stage 2: Selecting Channels and Materials
 What existing materials can be used or adapted?
 What formats will best suit the channels, messages, and audiences?
Stage 3: Developing and Pretesting Materials
 How can the messages be presented to the target audiences?
 What has message testing revealed about audience reaction, message clarity, recall,
acceptance, and value?
 What changes need to be made to the messages or their format, based on testing
responses?
Stage 4: Implementing the Program
 Are the messages making it through the communication channels to the audiences?
 Do any channels need to be changed? Do any new ones need to be added?
 What modifications need to be implemented?
Stage 5: Assessing Effectiveness
 Were the communications objectives met?
 Were the changes that took place the result of the program, other factors, or a
combination of both?
Stage 6: Feedback to Refine the Program
 What made this program work or not work?
 What changes should be made to improve the program or better reach the target
audience?
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GOAL VI: Track progress
Monitor progress toward the goal of TB elimination, and make regular reports on
progress to all target audiences.
Objective VI-A
Develop innovative analyses for examining surveillance data to help focus elimination
efforts.
Traditional analyses of surveillance data provide basic descriptive epidemiology, including case
counts and case rates by time, place, and case characteristics. Since 1993, the expanded TB
case report has provided additional information on TB risk factors, such as HIV status, initial
drug resistance, and treatment. These additional data elements have enhanced the ability at
local, state, and national levels to describe high-risk populations and assess program efforts to
ensure prompt and appropriate treatment for active cases. To better focus elimination efforts,
innovative analyses to supplement traditional analyses will be needed. For example, the
development of a definition of elimination for areas where annual case counts are very low
(e.g., <10) and population size fairly small (e.g., <100,000) will help pinpoint regions on track
for elimination.
Activities
1. Convene CDC work group(s) to define areas where innovative analyses would be most
useful and to devise strategies for development and implementation.
2. Conduct and disseminate the results of innovative analyses to better focus elimination
efforts.
Objective VI-B
Develop novel indicators of progress toward elimination.
Traditional program indicators included annual incident case counts and case rates, estimates of
primary and acquired drug resistance, and completion-of-therapy rates. Recently developed
indicators of successful contact investigations and targeted testing include completion-of-
therapy rates for persons identified with latent TB infection. As areas progress toward
elimination, further development of novel indicators will be essential.
Activities
1. Develop a CDC unit to work with partners from local, state, and federal levels to
periodically review standard indicators and develop new indicators for use in measuring
progress toward elimination.
2. Develop meaningful and useful reports for program officials and policy makers
highlighting national progress using these standard indicators.
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Objective VI-C
Conduct periodic evaluations of TB program performance at federal, state, and local
levels.
An important part of TB control efforts is continuous evaluation of the effectiveness of control
programs. Program evaluations provide 1) a feedback loop for data that can be used to refine
operations and procedures, 2) a rational basis for decisions about the relative value of
particular activities, and 3) information about ways to improve specific aspects of a given
program. Evaluations force persons close to a program to step back and examine their efforts
objectively. This is especially useful for well-intentioned programs that may be more
concerned about addressing the immediate TB treatment and control needs in their
communities than in determining the best ways to meet those needs. Methods to identify and
correct problems in TB control programs and systems must be developed before they result in
the further spread of TB disease and the development of drug-resistant TB.
Activities
1. Develop guidelines and standards for TB program evaluation.
 Conduct research to identify best methods for the evaluation of TB programs.
 Work with national organizations (e.g., ACET, NTCA, NCET) to develop guidelines
and standards for TB program evaluation.
 Disseminate guidelines and standards to state and local TB programs.
 Incorporate evaluation as a core component of TB prevention and control programs.
2. Develop the capacity for program evaluation at the federal, state, and local levels.
 Develop training in evaluation methods and techniques.
 Provide ongoing technical assistance in program evaluation.
 Develop information management systems to facilitate program evaluation.
 Provide funding for program evaluation, utilizing the results for strategic planning and
program enhancement.
Objective VI-D
Conduct an annual progress review.
Activities
1. Prepare annual progress reports for review by ACET and NTCA.
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